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Female participation in regular sport activities has increased in recent years, yet their 36 
representation in the sports and exercise science literature remains low. Therefore, an 37 
understanding of the effects different phases of the menstrual cycle (MC) have on 38 
exercise responses is important due to the practical and theoretical implications. The 39 
aim of this study was to compare performance, physiological and perceptual differences 40 
when performing a running repeated sprint ability (RSA) during the early-follicular (EF), 41 
and mid-luteal (ML) sub-phases of the MC. Six healthy, physically active female 42 
participants (age: 25.67 ± 2.49 years; height: 1.66 ± 0.08 m; body mass: 69.8 ± 19.3 kg; 43 
V̇O2peak: 46.00 ± 6.76 ml·kg1·min-1) took part in this study. After the initial health 44 
screening, the participants completed two familiarisation and four intervention sessions 45 
(twice during each MC sub-phase). The RSA protocol consisted of five ‘all-out’ sprints of 46 
six seconds on a non-motorised treadmill with 24 seconds of active recovery (walking) 47 
between the sprints. Results indicated no significant differences between MC sub-48 
phases in mean (p = 0.998, d = 0.00) and peak power output (p = 0.14, d = 0.16), distance 49 
(p = 0.59, d = 0.07), pre-exercise (p = 0.78, d = 0.41) and post-exercise lactate (p = 0.58, 50 
d = 0.24), oxygen uptake (p = 0.10, d = 0.30), respiratory exchange ratio (p = 0.47, d = 51 
0.13), ventilation (p = 0.42, d = 0.12), heart rate (p = 0.49, d = 0.17). However, significant 52 
differences were found in peak acceleration (EF: 4.65 ± 0.84 m·s-2, ML: 5.05 ± 1.14 m·s-53 
2) (p = 0.02, d = 0.40) and rating of perceived exertion (RPE) (EF: 13.42 ± 2.15, ML: 12.60 54 
± 2.26) (p < 0.001, d = 0.37). In conclusion, MC phases do not appear to influence most 55 
of the chosen RSA performance indicators. However, due to the low sample size and 56 
statistical power, further studies are required to better investigate the effects of the MC 57 
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1. Introduction 270 
1.1 Women in sport 271 
Most studies in sports and exercise sciences have been conducted on men, with the 272 
results generalised to women, without considering how the sex differences may affect 273 
the transferability of these results (Bruinvels et al., 2017; Sims & Heather, 2018). In fact, 274 
women have been, and still are, often excluded from sport and exercise research, or are 275 
often included together with men without giving much consideration to the 276 
physiological differences (Johnson, Greaves, & Repta, 2009). 277 
Female underrepresentation in sport and exercise research has been clearly shown by 278 
an analysis of 1382 articles from key sports and exercise science journals such as the 279 
British Journal of Sports Medicine, American Journal of Sports Medicine and Medicine 280 
and Science in Sports and Exercise, which indicated that only 39% of over six million 281 
participants in these studies were female (Costello, Bieuzen, & Bleakley, 2014). Out of 282 
all studies published in the American Journal of Sports Medicine between 2011 and 2013 283 
only 4% of them recruited female only participants compared to 18% that had male only 284 
and 78% that included both sexes (Costello et al., 2014). Frankovich & Lebrun (2000) and 285 
Sims & Heather (2018) indicated that some of the main reasons for the exclusion of 286 
females in research studies are the complexities associated with the menstrual cycle 287 
(MC), such as the biphasic response of oestrogen and progesterone, the high variability 288 
of hormone fluctuations throughout the day and the differences of hormone 289 
concentrations between persons. Moreover, studying the MC phases can be time 290 
consuming and expensive, as the gold standard in determining these phases require 291 
laboratory-based techniques such as blood samples analysis (Glass, 2001).  292 
Despite these challenges, sport and exercise science studies should not ignore the 293 





physiological measures. As failure to do so will prevent knowledge advancement and 295 
sporting performance optimisation in female participants. For example, training 296 
programmes cannot be optimised without the knowledge of the effects of the MC on 297 
performance. Therefore, in order to reduce the existing gap in literature between males 298 
and females, more female-only studies are required whilst carefully considering the 299 
effect that the MC phases may have on the outcome measures.  300 
1.2 Menstrual cycle 301 
The MC is governed by cyclic hormonal fluctuations that follow an established pattern 302 
of progesterone, oestrogen, luteinising hormone (LH) and follicle-stimulating hormone 303 
(FSH) (Frankovich & Lebrun, 2000). These hormones have previously been identified to 304 
affect female physiology and, in turn, may affect performance (Birch, 2000; Constantini, 305 
Dubnov, & Lebrun, 2005; Draper et al., 2018).  306 
For example, oestrogen affects metabolism by reducing gluconeogenesis and 307 
glycogenolysis (Bunt, 1990; D’Eon et al., 2002) and increasing fat oxidation, potentially 308 
affecting performance that relies on specific metabolic pathways to resynthesise energy 309 
(Nicklas, Hackney, & Sharp, 1989). In contrast, progesterone increases muscle glycogen 310 
utilisation (D’Eon et al., 2002), and has been recently demonstrated by Mata et al. (2019) 311 
to alter carbohydrate availability, thereby affecting performance and training 312 
adaptations. This indicates a link between hormonal fluctuations and both physiological 313 
and performance changes. 314 
1.2.1 Effects of the menstrual cycle on performance 315 
The physiological changes caused by oestrogen and progesterone during the MC sub-316 
phases might also affect physical performance, as shown by Julian et al. (2017) who 317 
reported a lower maximal endurance performance during the mid-luteal sub-phase 318 





reported that the lower performance, as measured by the total distance ran, might have 320 
been caused by an increase in body temperature due to the higher concentrations of 321 
progesterone, which can limit endurance performance and increase cardiovascular 322 
strain. McNulty et al. (2020) reviewed the current literature and concluded that 323 
performance might be trivially reduced during the early-follicular when compared with 324 
any other sub-phase. However, due to limitations in the studies, it is not possible to draw 325 
any conclusion (McNulty et al., 2020).  326 
Therefore, studying the effects of the different sub-phases of the MC on physical 327 
performance can benefit both athletic and general population by helping inform and 328 
implement an evidence-based approach, to reach a higher performance level or to 329 
improve their fitness and health. As these benefits might differ based on the type of 330 
performance chosen, and since previous research focused mostly on endurance aspects, 331 
there is a need to understand other forms of performance. Interestingly, only Giacomoni 332 
et al. (2000), Middleton & Wenger (2006) and Julian et al. (2017) focused on exercise 333 
performance shorter than 10 seconds, and no studies have analysed the running 334 
repeated sprint ability. Due to its importance in team sports but also its use as an 335 
exercise modality by general population, this study will focus on running repeated 336 
sprints performance. 337 
1.2.2 Repeated sprint ability 338 
Repeated Sprint Ability (RSA) is defined as the ability to perform repeated sprints with a 339 
short, incomplete recovery between repetitions (Bishop, Girard, & Mendez-Villanueva, 340 
2011). The repeated sprint ability is considered an important factor for team sports’ 341 
athletes, as being able to perform several sprints consecutively, with an incomplete rest, 342 
is a common situation in these sports (Bishop et al., 2011; Buchheit, Mendez-villanueva, 343 
Simpson, & Bourdon, 2010). Recently, the effectiveness of repeated sprint exercise has 344 





to increase aerobic fitness and decrease body fat in inactive overweight/obese women 346 
(Rowley, Espinoza, Akers, Wenos, & Edwards, 2017), as well as reduce low-density 347 
lipoproteins (LDL) and total cholesterol in young healthy participants (Sandvei et al., 348 
2012). 349 
Therefore, assessment of repeated sprint ability responses in different MC sub-phases 350 
has important practical and theoretical implications. From a practical point of view, 351 
knowing how different aspects of performance are influenced by MC sub-phases could 352 
help coaches and sport scientists tailor their schedules and programmes in order to 353 
maximise performance. From a theoretical point of view, it could benefit future 354 
researchers in this under-researched field by informing future research design and 355 
providing new data for comparison purposes. 356 
To date there is very limited research on the effects the MC has on athletic performance, 357 
as only Middleton & Wenger (2006) studied the effects of the MC phases on RSA 358 
performance, analysing 10 sprints of six seconds each with 30 seconds recovery on a 359 
cycle ergometer. They reported the average work over a series of sprints and oxygen 360 
uptake (V̇O2) between sprints to be higher during the luteal phase than the follicular 361 
phase. However, Middleton & Wenger (2006) only analysed a cycling performance, 362 
whilst running RSA has never been studied before. Analysing running RSA performance 363 
is important because the results could be applied in a multitude of sport activities both 364 
in athletes and/or general population, where running modality is common. 365 
1.3 Project’s aim 366 
Therefore, the aim of this study was to measure physiological, performance and 367 
perceptual responses during a running RSA at the early-follicular and mid-luteal sub-368 





hormonal differences, allowing a clearer understanding of the effects this may have on 370 





2. Literature review 372 
The current female-specific sport science literature, particularly in high-level athletes is 373 
scarce (Emmonds, Heyward, & Jones, 2019), and there is a clear disparity between the 374 
number of papers analysing females and males (Emmonds et al., 2019). Due to this lack 375 
of data, researchers cannot draw effective conclusions about the influence the MC has 376 
on sport performance, and practitioners cannot follow an evidence-based approach in 377 
their work (Emmonds et al., 2019). Therefore, there is a clear need to do more female-378 
specific research, but the first step would be to analyse the current literature available 379 
to understand the present situation and recognise the limitations (Emmonds et al., 380 
2019).  381 
A total number of 42 papers published between 1981 and 2019 were identified and 382 
analysed for the purpose of this literature review. Papers with keywords like “menstrual 383 
cycle” and “performance”, “physical activity” or “sport” were searched on PubMed and 384 
Google Scholar, and then only papers related to “sprinting”, “endurance” or 385 
“intermittent activity” were chosen for review. Details of the chosen papers are 386 
presented in Table 1. 387 
Table 1: details of the published papers included in this literature review. 388 









9 Active MF, ML Blood samples IETE (cycle) HR, lactatea, 
V̇O2, V̇e 
Schoene et al. 
(1981) 
12 Active / 
Non 
active 
MF, ML Blood samples, 
BBT 




6 Active Days 2, 
8, 14, 
20, 26 
Diary only 5 min at 4 submaximal 





Prevost et al. 
(1984) 
7 No info Ovulatio
n, days 
1, 2 
BBT 9 min cycling at increasing 




Bale & Nelson 
(1985) 
20 Active Days 1, 
8, 12-15, 
21 







9 Active / 
Non 
active 






MF, ML Blood samples IETE; 4 min constant-load 






Nicklas et al. 
(1989) 
6 Active MF, ML Blood samples, 
BBT 
SETE at 70% V̇O2max preceded 
by 90 min at 60% V̇O2max and 
4x1 min sprints (cycle) 
RPE, lactate, 
V̇O2, RER 
De Souza et al. 
(1990) 
8 Active EF, ML Blood samples, 
urine 






V̇e, RER, V̇O2 
Hackney et al. 
(1991) 















Diary only 100 m; 200 m (swim) n/a 
Pivarnik et al. 
(1992) 
9 Active MF, ML Blood samples, 
urine 







9 Active MF, ML Urine, BBT IETE (run) Lactatea 
Lebrun et al. 
(1995) 
16 Active EF, ML Blood samples, 
BBT 






Bemben et al. 
(1995) 




IETE (run) HR, lactate, 
V̇O2max, V̇e, 
body comp  
Miskec et al. 
(1997) 
10 Active L, 
menses 























8 Active EF, ML Blood samples, 
urine 
IETE; SETE at 70% V̇O2max (run) RPE, 
V̇O2max, 
















F, L Blood samples, 
urine 
IETE; 20 min at 25% V̇O2max 












7 Active MF, ML Blood samples LIST (run) RPE, HR, 
lactate 
Dean et al. 
(2003) 



























7 Active L, 
menses 
Urine, BBT Margaria-Kalamen; WAnT Power 
Smekal et al. 
(2007) 
19 Active F, L Blood samples, 
BBT 




Gurd et al. 
(2007) 
7 Active MF, ML Blood samples Incremental three steps 




et al. (2010) 













Vaiksaar et al. 
(2011) 









EF, LF, L Unknown 30 min at 65% V̇O2max (run) RPEa 
Shaharudin et 
al. (2011) 
12 Active MF, ML Blood samples, 
BBT 
3 sprints at 120% VO2max, 20 
min recovery (cycle) 
Lactate 







BBT 20 m SRT V̇O2max 
Janse de 
Jonge et al. 
(2012) 
8 Active EF, ML Blood samples, 
BBT 






et al. (2013) 




Wiecek et al. 
(2016) 
16 Active MF, ML Blood samples, 
BBT 




et al. (2016) 
8 Active MF, LL Diary only Upper limbs WAnT; SJFT Lactate, 
power, 
fatigue 
Pestana et al. 
(2017) 







Julian et al. 
(2017) 
9 Active EF, ML Blood samples Yo-Yo IET, 3x30 m sprints, 2 min 
recovery (run) 
Body comp 
Köse (2018) 10 Active EF, MF, 
L 
Diary only WAnT, IETE (walk) HR, power 
Gordon et al. 
(2018) 









et al. (2019) 
12 Active F, L, 
ovulatio
n 
Blood samples n/ac RPE 
Mattu et al. 
(2019) 
15 Active MF, ML Urine Incremental three steps 






L: Luteal; F: Follicular; EL: Early-luteal; ML: Mid-luteal; LL: Late-luteal; EF: Early-follicular; MF: Mid-follicular; LF: Late-389 
follicular; BBT: Basal Body Temperature; Ve: Ventilation; HR: Heart Rate; RPE: Rating of Perceived Exertion; RER: 390 
Respiratory Exchange Ratio; PPO: Peak Power Output; WAnT: Wingate Anaerobic Test; IETE: Incremental Exercise To 391 
Exhaustion; LIST: Loughborough Intermittent Shuttle Test; SRT: Shuttle Run Test; SJFT: Special Judo Fitness Test; IET: 392 
Intermittent Endurance Test; SETE: Submaximal Exercise To Exhaustion; TTE (Time To Exhaustion); AST (Anaerobic 393 
Speed Test) 394 
a Results with a significant difference between menstrual cycle phases 395 
b Sample size may differ from the original paper, excluding participants using oral contraceptives or amenorrheic 396 
c A technical training session was analysed, containing multiple kind of movements 397 
d Not all the parameters are shown here, but only the one also analysed in this project 398 
2.1 Menstrual cycle 399 
The MC is an important biological rhythm which main purpose is to prepare the uterus 400 
for possible pregnancy (Stefanovsky, Peterova, Vanderka, & Lengvarsky, 2016). In 401 
addition to regulating the reproductive function, the MC affects a wide range of 402 
physiological functions and responses, including the characteristics of the epidermis, 403 
hair growth, immune function and disease susceptibility (Farage, Neill, & MacLean, 404 
2009). As shown in Table 2, the MC is governed and characterised by cyclic fluctuations 405 
of oestrogen and progesterone that are regulated using a negative and positive feedback 406 
system that controls the MC (Thiyagarajan, Basit, & Jeanmonod, 2020), and have been 407 
identified to lead to physical and psychological changes, which subsequently might 408 






Table 2: typical hormones range during the menstrual cycle[a].  411 
Phases (days on a 28-day cycle) Oestradiol (ng/mL) Progesterone (ng/mL) LH (mUS/mL) 
Menses (1-4) 20 – 60 <2 5 – 25 
Early-follicular (4-5) 20 – 100 <2 5 – 25 
Mid-follicular (5-7) 100 – 200 <2 5 – 25 
Late-follicular (8-12) >200 <2 5 – 25 
Ovulation (13-15) >200 2 – 20 25 – 100 
Early-luteal (16-20) 100 – 200 2 – 20 5 – 25 
Mid-luteal (21-23) 100 – 200 2 – 30 5 – 25 
Late-luteal (24-28) 20 – 60 2 – 20 5 – 25 
[a] (Allen et al., 2016) 412 
A regular MC lasts between 24 and 35 days, with an average of 28 days, and it can be 413 
divided into three phases: follicular (proliferative), ovulatory and luteal (secretory) 414 
(Figure 1) (F. C. Baker & Driver, 2007; Gordon et al., 2018; Lebrun, McKenzie, Prior, & 415 
Taunton, 1995). Furthermore, the follicular and luteal phases can be divided into sub-416 
phases: early, mid and late (Lebrun et al., 1995).  417 
The follicular phase is the first part of the ovarian cycle, which starts with menses and 418 
ends with ovulation (Frankovich & Lebrun, 2000). During this phase, the hypothalamus 419 
releases the gonadotropin-releasing hormone (GnRH), which stimulates the anterior 420 
pituitary to secrete LH and FSH (Barbieri, 2014; Thiyagarajan et al., 2020). According to 421 
the two-cell two-gonadotropin theory, LH stimulates thecal cells in order to produce 422 
androgens, whilst FSH stimulates the granulosa cells to produce oestrogen from these 423 
androgens (Enea, Boisseau, Fargeas-Gluck, Diaz, & Dugué, 2011). Even though both LH 424 
and FSH release is stimulated by the GnRH, they are released differently throughout the 425 
MC. This difference is modulated by GnRH pulse frequency, where slow frequencies 426 
favour FSH secretion and fast frequencies favour LH secretion, inhibin A and B, which 427 
inhibit FSH secretion, and activins, which stimulate FSH secretion (Barbieri, 2014). 428 
In this period the follicles grow under the influence of FSH which upon release also 429 
increases the synthesis of oestrogen, whose role is to thicken the endometrium to 430 
prepare for the coming egg and for possible pregnancy (Constantini et al., 2005; 431 





the secretion of LH, which will trigger the ovulation at the end of the follicular phase 433 
(Constantini et al., 2005; Frankovich & Lebrun, 2000; Su, Yi, Wei, Chang, & Cheng, 2017).  434 
The duration of the follicular phase, on average, lasts 12-14 days and it is characterised 435 
by initial low concentrations of oestrogen and progesterone (Frankovich & Lebrun, 2000; 436 
Sims & Heather, 2018). However, the hormonal concentrations change throughout this 437 
phase. Specifically, the early-follicular sub-phase (EF) is characterised by low 438 
concentrations of both oestrogen and progesterone, the mid-follicular sub-phase (MF) 439 
being characterised by low concentrations of progesterone and raising concentrations 440 
of oestrogen, and the late-follicular sub-phase (LF) characterised by a low concentration 441 
of progesterone and high concentrations of oestrogen (Janse de Jonge, 2003).  442 
At the end of the follicular phase, the ovulatory phase occurs. During the ovulation, an 443 
exception to the negative-feedback system occurs, where an increase in oestrogen will 444 
provide a positive feedback to produce FSH and LH, called LH surge (Stefanovsky et al., 445 
2016; Thiyagarajan et al., 2020).The LH surge will cause the mature follicle to release the 446 
egg (ovulation) from a woman’s ovary (Barbieri, 2014; Stefanovsky et al., 2016). From 447 
the ovary, the egg travels to the fallopian tubes where the potential of fertilisation may 448 
occur (Jonge, 2009). 449 
The luteal phase is the latter phase of the MC, which begins with ovulation and ends at 450 
the start of menses (Frankovich & Lebrun, 2000). In this phase an empty follicle 451 
transforms into a structure known as corpus luteum, which acts to stabilise the 452 
endometrium for implantation of the fertilised egg (Frankovich & Lebrun, 2000). When 453 
fertilisation or implantation do not occur, the corpus luteum will begin to break down 454 
(Frankovich & Lebrun, 2000). As the secretory phase ends, the negative feedback from 455 
progesterone to the anterior pituitary will decrease FSH and LH levels, which will cause 456 





progesterone, called progesterone withdrawal, will lead to the start of another 458 
menstrual period (Frankovich & Lebrun, 2000; Stefanovsky et al., 2016).  459 
On average, the luteal phase lasts 12-14 days, and is characterised by high 460 
concentrations of oestrogen and progesterone (Sims & Heather, 2018). Similar to the 461 
follicular phase, the luteal phase can be divided into three sub-phases. The early-luteal 462 
sub-phase (EL), which is characterised by decreasing concentrations of oestrogen and 463 
raising concentrations of progesterone. The mid-luteal sub-phase (ML), described by 464 
high concentrations of both oestrogen and progesterone. And the late-luteal (LL) sub-465 
phase, which is characterised by a decrease of progesterone and oestrogen (Janse de 466 













2.2 Effects of hormones 472 
Throughout the MC there is an established pattern of hormonal changes that involves 473 
progesterone, oestrogen, LH and FSH (Frankovich & Lebrun, 2000). These hormones 474 
have also been found to affect several other functions not related to the reproductive 475 
function, but that can affect aspects related to physical performance, such as the 476 
cardiovascular and respiratory systems. Whilst oestrogen and progesterone change a lot 477 
between the different phases, FSH and LH concentrations are more stable between the 478 
early-follicular and mid-luteal sub-phases (Figure 2), and therefore it can be assumed 479 
that they will be more consistent in their effects on performance during the MC. 480 
 481 
Figure 2: menstrual cycle hormonal fluctuations (Ocampo Rebollar, Menéndez Balaña, & Conde Pastor, 2017). 482 
2.2.1 Oestrogen 483 
When investigating the hormonal effect on physical performance, oestrogen was found 484 
to affect energy metabolism by increasing the muscle glycogen storage and repletion, as 485 
well as being direct mobilisers of adipocyte free fatty acid (FFA) (Oosthuyse, Bosch, & 486 
Jackson, 2005). As a result of the increased use of fat oxidative pathways a lower 487 
respiratory exchange ratio (RER) occurs (Nicklas et al., 1989), which subsequently results 488 
in a glycogen-sparing effect (Smekal et al., 2007). The enhanced glycogen repletion and 489 
higher fat usage particularly benefits submaximal endurance exercises (Nicklas et al., 490 





utilisation, by increasing triglyceride synthesis and lipolysis in muscle and adipose tissue 492 
and decrease gluconeogenesis and glycogenolysis by increasing the ratio between 493 
insulin and glucagon. Furthermore, D’eon et al. (2002) reported that increased 494 
concentrations of oestrogen were found to lower carbohydrate oxidation during 495 
submaximal exercise, by reducing muscle glycogen utilisation, without affecting blood 496 
glucose uptake. However, the authors reported that this change in carbohydrate 497 
oxidation and reduced muscle glycogen usage did not seem to affect performance as 498 
measured by HR and V̇O2. 499 
Oestrogen is also known to have an influence on pain by reducing some types of pain 500 
such as migraine or arthritis (Hooper, Bryan, & Eaton, 2011). However, due to the 501 
oestrogen’s effects on several systems, including the nervous and the immune systems, 502 
oestrogen can produce both pro and antinociceptive effects, and the mechanisms 503 
underlying this modulation are specific to each kind of pain (Craft, 2007). For example, 504 
oestrogen alter opioid antinociceptive pathways and suppress adrenergic 505 
antinociception, with which they modulate different types of pain such as 506 
musculoskeletal pains (Craft, 2007). This is particularly important, as pain influences 507 
players ability to fully participate in training and/or competition, and also affects other 508 
aspects such as rehabilitation programmes (Kakiashvili, Tsagareli, Mjavanadze, & 509 
Kvachadze, 2016). This was further confirmed by Hooper et al. (2011) who reported 510 
higher RPE during the early-follicular sub-phase than the late-follicular and the luteal 511 
phase. Furthermore, Hooper et al. (2011) reported that changes in RPE during the MC 512 
phases might be due to changes in pain experienced whilst performing during the same 513 
phases. Thus, based on the current literature it appears that oestrogen fluctuations 514 
affect different systems and functions, such as the nervous system, energy metabolism 515 






2.2.2 Progesterone 518 
Previous studies on the effects of progesterone on cardiac function suggest that 519 
progesterone increases heart rate by shortening the cardiac action potential, due to 520 
changes in myocardial L-type calcium channel current, potassium channel currents and 521 
inward rectifier current (Sedlak, Shufelt, Iribarren, & Merz, 2012). Furthermore, 522 
progesterone has been shown to stimulate ventilation by stimulating chemoreceptors 523 
(Williams & Krahenbuhl, 1997), which could lead to a lower V̇O2max and therefore to a 524 
decrease in performance (Abdollahpor, Khosravi, & Zahra, 2013). Progesterone has also 525 
been found to have metabolic effects, stimulating deposition of body fat by reducing 526 
sensitivity of adipocytes to insulin-induced glucose uptake and oxidation, and having a 527 
catabolic effect on protein metabolism (Kalkhoff, 1982). As performance in prolonged 528 
exercise relies on fat oxidation consequently, a lower availability of this energy source 529 
may negatively impact performance (Maunder, Plews, & Kilding, 2018).  530 
Therefore, it appears that these negative effects associated with progesterone are more 531 
apparent during the luteal phase, when progesterone concentrations are highest. 532 
Furthermore, it appears that oestrogen and progesterone have contrasting effects on 533 
energy metabolism, with oestrogen increasing the muscle glycogen storage and 534 
repletion, as well as being direct mobilisers of adipocyte free fatty acid (FFA), and 535 
progesterone stimulating deposition of body fat by reducing sensitivity of adipocytes to 536 
insulin-induced glucose uptake and oxidation.  537 
2.3 Menstrual cycle phases definition 538 
As oestrogen and progesterone cause modifications in cardiovascular and metabolic 539 
parameters this has important implications for endurance performance (Constantini et 540 
al., 2005). Considering that these hormones fluctuate greatly between different phases 541 





Furthermore, as oestrogen and progesterone are not constant and change throughout a 543 
single phase, the definition of sub-phases is also fundamental in defining the effects 544 
hormonal concentrations have during each sub-phase (Allen et al., 2016). However, even 545 
though defining the sub-phases is of primary importance, Masterson (1999), Redman et 546 
al. (2003), Smekal et al. (2007), Tsampoukos et al. (2010), Vaiksaar et al. (2011) and 547 
Cristina-Souza et al. (2019) did not take into consideration any sub-phases, and only 548 
focused on the differences between the main MC phases. 549 
Furthermore, the definition of the MC sub-phases is often unclear, as when referring to 550 
a 28-day MC, different authors associated sub-phases with different days, leaving some 551 
degree of uncertainty when comparing different papers (Table 3). This inconsistency in 552 
the association between specific sub-phases and days of the MC is likely to cause 553 
methodological errors, because different papers might declare to be comparing different 554 
sub-phases whilst using the same days. Additionally, this brings a great level of confusion 555 
for sport and exercise scientists looking for specific information and should therefore be 556 
addressed in future studies. For example, the early-follicular sub-phase definitions range 557 
from 1-5 days (Hooper et al., 2011) to 3-8 days (Lebrun et al., 1995). At the same time, 558 
different authors define the mid-follicular sub-phase starting on the 5th (Mattu, Iannetta, 559 
MacInnis, Doyle-Baker, & Murias, 2019), 6th (Middleton & Wenger, 2006; Shaharudin, 560 
Ghosh, & Ismail, 2011), or 7th day (Giacomoni, Bernard, Gavarry, Altare, & Falgairette, 561 
2000; Pestana et al., 2017), overlapping with Lebrun et al.’s (1995) definition for the 562 
early-follicular sub-phase (Table 3). Similarly, an overlap is seen in the mid-follicular sub-563 
phase around the 9th and 10th days, where Hooper et al. (2011) labels these days as late-564 
follicular (Table 3) whilst Pestana et al. (2017), Middleton & Wenger (2006), Shaharudin 565 
et al. (2011), and Mattu et al. (2019) all defined these days as mid-follicular. 566 
Furthermore, in one specific case the exact same days are defined as two different sub-567 





and 24th day, but the same days were used by Middleton & Wenger (2006) to define the 569 
late-luteal sub-phase (Table 3). 570 
Table 3: different definitions of each sub-phase, used by different authors. 571 
Authors EF MF LF ML LL 
Hooper et al. (2011) 1 – 5  9 – 15   
Bemben et al. (1995) 2 – 5  12 – 15 20 – 23  
Lamont (1986) 2 – 4   20 – 22  
Janse de Jonge (2003) 3 – 6   19 – 25  
Julian et al. (2017) 5 – 7   21 – 22  
Mattu et al. (2019)  5 – 10  19 – 24  
Shaharudin et al. (2011)  6 – 10  20 – 24  
Gordon et al. (2018)  9 – 11  19 – 20  
Giacomoni et al. (2000)  7 – 9  19 – 21  
Middleton & Wenger (2006)  6 – 10   20 – 24 
Pestana et al. (2017)  7 – 9 10 – 14  26 – 28 
Oosthuyse et al. (2005) 2 – 7  From 2d before LH 
surge to LH surge 
4 – 10 after LH surge  
De Souza et al. (1990) 2 – 4   6 – 8 from LH surge  
Beidlemn et al. (1999) 3 – 6   6 – 9 after LH surge  
Lebrun et al. (1995) 3 – 8   4 – 9 after ovulation  
Schoene et al. (1981)  6 – 10  4 – 9 after ovulation  
Nicklas et al. (1989)  7 – 8  7 – 8 after ovulation  
Jurkowski et al. (1981)  6 – 9  6 – 9 after ovulation  
McCracken et al. (1994)  6 – 9  6 – 9 after ovulation  
Dombovy et al. (1987)  7 – 11  3 – 11 days before 
expected menses 
 
EF: Early-follicular, MF: Mid-follicular, LF: Late-follicular, ML: Mid-luteal, LL: Late-luteal 572 
From Table 3 it can be noted that, whilst Hooper et al. (2011), Bemben et al. (1995), 573 
Lamont (1986), Janse de Jonge (2003), Julian et al. (2017), Mattu et al. (2019), 574 
Shaharudin et al. (2011), Gordon et al. (2018), Giacomoni et al. (2000), Middleton & 575 
Wenger (2006) and Pestana et al. (2017) used specific days to identify the sub-phases, 576 
based on a 28-day cycle, Oosthuyse et al. (2005), De Souza et al. (1990), Beidlemn et al. 577 
(1999), Lebrun et al. (1995), Schoene, Robertson, Pierson, & Peterson (1981), Nicklas et 578 
al. (1989), Jurkowski et al. (1981) and McCracken et al. (1994) used the ovulation or the 579 
LH surge as a starting point to count for the luteal phases. Using the ovulation or the LH 580 
surge means that the follicular phase length might not be 14 days. However, using this 581 





if ovulation occurred on two different days, the instructions (i.e. number of days) to 583 
determine the luteal sub-phases would not change. Even though using the LH surge or 584 
the ovulation accounts for a different follicular phase duration between different 585 
participants, no solutions have been proposed to account for the luteal phase, which is 586 
just assumed to be exactly the same between all participants. However, the luteal phase 587 
has been demonstrated to vary significantly, as Liu et al. (2004) reported that luteal 588 
phase can be shorter than 11 days or longer than 15 days. 589 
Furthermore, when a MC is not 28-days long, there are no clear references on how to 590 
divide the sub-phases. All the indications provided are based on an average 28-days long 591 
MC, but this is often not the real length of the cycle, as shown by the different mean MC 592 
length in several papers. For instance, Shaharudin et al. (2011) reported a mean length 593 
of 30.3 ± 2.1 days for the MC, but still provided a division in sub-phases based on a 28-594 
day MC. Therefore, it is unknown as to how they determined specific sub-phases in all 595 
individual participants with different MC lengths. 596 
A recent systematic review by Schmalenberger et al. (2019) proposed a new definition 597 
of the sub-phases, completely changing the way they have been described until now. 598 
This reclassification, shown in Table 4, is based on hormone concentrations and 599 
therefore it can only be used when hormones are collected and analysed. However, from 600 
a practical point of view this might not be possible for coaches/practitioners due to the 601 
high cost, the invasiveness, and the need for competent staff to collect and analyse 602 
hormonal data. If a cheaper, simpler, yet accurate way to determine hormones is made 603 
available by future technologies, then it could become the more convenient way to 604 







Table 4: menstrual cycle phases’ reclassification proposed by Schmalenberger et al. (2019). 608 
Phase Hormone concentrations 
Menstrual phase Low oestrogen, low progesterone 
Mid-to-late-follicular phase Rising oestrogen, low progesterone 
Ovulatory phase Peak oestrogen, low progesterone 
Early-to-mid-luteal phase Secondary lesser peak of oestrogen, peak progesterone 
Premenstrual phase Falling oestrogen, falling progesterone 
 609 
2.4 Menstrual cycle determination 610 
An important aspect in the determination of the MC sub-phases is the method by which 611 
these sub-phases are assessed (Allen et al., 2016). Using different methods to determine 612 
the MC sub-phases can result in having the same days defined as two different sub-613 
phases, and therefore creating a problem interpreting and comparing the results. This 614 
may also explain the inconsistent definitions of MC sub-phases between studies as 615 
described in the previous section. 616 
The choice of the appropriate method to determine the MC should be based on its 617 
accuracy, the cost, and the invasiveness, as shown in Table 5. All of these different 618 
methods can impact on the classification of the sub-phases of the MC (Allen et al., 2016) 619 
and the accuracy is certainly a fundamental aspect to consider. However, the cost and 620 
invasiveness are also important when choosing the method for MC determination, 621 
especially for the use of non-clinical practice including sports practitioners. As even if 622 
they understand the advantages of monitoring the MC, the cost and invasiveness of the 623 









Table 5: cost, invasiveness, and accuracy of each method for menstrual cycle phases’ determination. 629 
Method Cost (1 – 3)* Invasiveness Sub-phase identification accuracy 
Diary 1 Very low Low 
BBT 2 Low Medium 
Urinary LH 2 Low Medium** 
Salivary analysis 3 Medium High** 
Blood analysis 3 Medium High 
Adapted from (Allen et al., 2016) 630 
* 1 is the lowest cost, 3 is the highest 631 
** The accuracy was found to be higher with the urinary kit, when compared with salivary analysis, by Eichner & 632 
Timpe (2004) 633 
When assessing the time of ovulation or the different sub-phases of the MC, a number 634 
of different methods are available (Su et al., 2017). Blood sample analysis is considered 635 
to be the gold standard (Frankovich & Lebrun, 2000; Janse de Jonge, 2003) as it provides 636 
specific hormonal values that can be used to confirm MC sub-phases. However, this 637 
method is expensive and invasive (Su et al., 2017), which limits its application to general 638 
use. Other methods that may be utilised include urinary kits, basal body temperature, 639 
salivary analysis and a diary-based approach (Su et al., 2017). 640 
The urinary kits have been shown to be an accurate and reliable method to identify 641 
ovulation, and it is considered to be superior to basal body temperature, calendar-based 642 
and salivary analysis methods (Eichner & Timpe, 2004; Miller & Soules, 1996; Su et al., 643 
2017). A study by Guida et al. (1999) compared different methods to detect ovulation 644 
such as salivary hormones, basal body temperature and urinary kits and concluded that 645 
the determination of urinary LH concentrations should be the preferred method for 646 
defining ovulation. A commonly used urinary kit to determine ovulation is the Clearblue 647 
Advanced Digital Ovulation Test, which has been recently used by Mattu et al. (2019). 648 
The manufacturer of the Clearblue Advanced Digital Ovulation Test declares an accuracy 649 
of 99% in detecting the LH surge, and can therefore be considered reliable (Mattu et al., 650 
2019). However, even though urinary kits are considered accurate and reliable when 651 
identifying ovulation, they do not measure hormone concentrations, and therefore 652 





MC sub-phases would be counted/predicted based on the ovulation and the average MC 654 
length, instead of being directly determined. 655 
Monitoring of basal body temperature is reported as one of the simplest and least 656 
invasive methods to detect ovulation (Allen et al., 2016). Researchers have previously 657 
identified that core body temperature usually decreases to its lowest point one day 658 
before ovulation, and then rises during the luteal phase to a higher level than the 659 
follicular phase (increase of 0.28 to 0.56°C) (Barron & Fehring, 2005). However, this 660 
method is not considered accurate, as some women have been found to ovulate without 661 
a clear rise in temperature, and therefore should not be used to predict ovulation 662 
(Barron & Fehring, 2005). The number of women experiencing ovulation without a rise 663 
in temperature has been reported to range between 20 and 22.1% (Bauman, 1981; 664 
Moghissi, 1976). Furthermore, other factors might impact the basal body temperature, 665 
such as fever, alcohol consumption, climate changes or emotional and physical stress (Su 666 
et al., 2017), thus creating difficulties in the interpretation of the basal body 667 
temperature. 668 
Salivary analysis is another method to determine the MC by measuring hormone 669 
concentration in a saliva sample. However, this method has been previously reported to 670 
be less accurate than the use of blood samples, yet more accurate than the body 671 
temperature monitoring (Allen et al., 2016; Su et al., 2017). In addition, when comparing 672 
salivary analysis with the LH urinary kit, different results have been found. Whilst Allen 673 
et al. (2016) reported salivary analysis to be more accurate than the use of a urinary kit, 674 
Eichner & Timpe (2004) reported a higher accuracy for the urinary kit compared with the 675 
salivary analysis when determining MC sub-phases. These differences between studies 676 
might be explained by the accuracy of each method and any other discrepancies in the 677 





The accuracy of a calendar-based method has previously been analysed by Wideman et 679 
al. (2013), concluding that a self-reported history and a diary should not be used to 680 
determine ovulation because of its low accuracy. Nonetheless, Wideman et al. (2013) 681 
suggest that a urinary kit and serial blood samples would provide better results than the 682 
calendar-based method for the identification of the MC sub-phases, due to its enhanced 683 
chances to properly identify MC events. 684 
The aforementioned methods can be used together in a combined approach, to increase 685 
the probability to identify the correct sub-phases (Schaumberg, Jenkins, Janse de Jonge, 686 
Emmerton, & Skinner, 2017). Different authors have utilised a variety of different 687 
combinations of methods to increase the accuracy in identifying the correct sub-phases, 688 
as shown in Table 6. For example, Mattu et al. (2019) utilised a urinary kit and a calendar-689 
based approach. Whereas, Hackney et al. (1991) and Oosthuyse et al. (2005) combined 690 
four methods (blood sample analysis, urinary kit, basal body temperature monitoring, 691 
diary) to determine the MC sub-phases. Blood samples analysis have also been used in 692 
combination with a urinary kit and a diary to determine the MC sub-phases (Beidleman 693 
et al., 1999; De Souza, Maguire, Rubin, & Maresh, 1990; Pivarnik, Marichal, Spillman, & 694 
Morrow, 1992; Redman, Scroop, & Norman, 2003; Tsampoukos, Peckham, James, & 695 
Nevill, 2010). A recent review by Janse de Jonge et al. (2019) suggested that the best 696 
approach would be a combination using a calendar-based method to count the days, a 697 
urinary kit to detect ovulation and the measurement of serum oestrogen and 698 
progesterone the day of the testing, to confirm whether or not the test was done in the 699 
correct MC phase, based on expected hormonal concentrations in each one (EF: low 700 
oestrogen and progesterone; LF: oestrogen higher than EF and ML and progesterone 701 







Table 6: combined approaches used by different authors to determine the menstrual cycle phases. 705 
References Combined approach utilised 
Hackney et al. (1991), Oosthuyse et al. (2005) Blood samples + urinary kit + temperature + calendar 
De Souza et al. (1990), Pivarnik et al. (1992), 
Tsampoukos et al. (2010), Redman et al. (2003), 
Beidleman et al. (1999) 
Blood samples + urinary kit + calendar 
Schoene et al. (1981), Shaharudin et al. (2011), Lebrun 
et al. (1995), Bemben et al. (1995), Nicklas et al. (1989), 
Wiecek et al. (2016), Williams et al. (1997), Janse de 
Jonge et al. (2012), Dean et al. (2003) 
Blood samples + temperature + calendar 
Smekal et al. (2007) Blood samples + temperature 
Bushman et al. (2006), McCracken et al. (1994) Urinary kit + temperature + calendar 
Mattu et al. (2019) Urinary kit + calendar 
 706 
As the MC phases and sub-phases are based on a regular ovulatory cycle, an important 707 
aspect to consider is the possibility of a luteal phase-deficient (LPD) or anovulatory cycle, 708 
characterised by a lower LH surge and reduced hormone production (Janse De Jonge, 709 
Thompson, & Han, 2019). A regular MC with normal bleeding is not enough to confirm 710 
ovulation, as these ovulatory disturbances can occur without showing anything 711 
abnormal nor any particular symptoms (Janse de Jonge et al., 2019; Schliep et al., 2014). 712 
Luteal phase-deficient or anovulatory cycles are common in physically active females, 713 
with approximately 50% of exercising women experiencing LPD or anovulation (De Souza 714 
et al., 2010). It is also important to mention that over one third of menstrual cycles are 715 
anovulatory even in healthy females, and it is believed that those cycles occur in all 716 
women (Prior, Naess, Langhammer, & Forsmo, 2015). Therefore, when studying females 717 
and their MC, it is important to accurately verify if participants are experiencing these 718 
conditions or not (Janse de Jonge, 2003). LPD and anovulatory cycles are characterised 719 
by low progesterone during the luteal phase when compared to a normal ovulatory 720 
cycle. Therefore, the inclusion of participants with LPD or anovulatory cycles potentially 721 
influences the results of a study (Birch, 2000; Janse de Jonge, 2003). 722 
Among the different methods to determine the MC phases and sub-phases, some of 723 





Jonge et al., 2019). The calendar-based approach and the basal body temperature, both 725 
on their own or combined, cannot dismiss an anovulatory or LPD cycle (Schliep et al., 726 
2014; Wideman, Montgomery, Levine, Beynnon, & Shultz, 2013). The urinary kit, 727 
however, can exclude anovulatory cycles, but cannot exclude LPD cycles (Janse De Jonge 728 
et al., 2019). Salivary hormones analysis can be used to exclude both anovulatory and 729 
LPD cycles, but due to the low concentration of hormones in saliva, tests with a very high 730 
sensitivity are needed along with multiple samples (Janse De Jonge et al., 2019). Blood 731 
sample hormone analysis have been considered the main method to verify that both LPD 732 
and anovulatory cycles are excluded (Janse de Jonge et al., 2019). Therefore, the blood 733 
sample hormone analysis should be considered the gold standard because it is, among 734 
the above-mentioned methods, the only one that can guarantee both a precise 735 
determination of the MC phases whilst also excluding LPD and anovulatory cycles (Janse 736 
de Jonge et al., 2019). However, blood sample hormone analysis is expensive, time-737 
consuming and requires a high level of expertise, which reduces its practical applications 738 
in an applied sport environment. 739 
2.5 Effects of hormones on participant’s characteristics 740 
Participant’s characteristics such as body mass and body composition have been 741 
analysed previously, as they have been deemed by researchers to affect performance 742 
(Esco et al., 2018; Maciejczyk, Wiecek, Szymura, Szygula, & Brown, 2015). The effects of 743 
the MC on body mass and body composition have been studied because it has been 744 
hypothesised that changes could occur due to changes in fluid regulation (Giacomoni et 745 
al., 2000; Janse de Jonge, 2003). However, no previous studies that measured body mass 746 
and/or body composition between the sub-phases have found significant differences in 747 
either of those parameters. 748 
The differences in body mass and body composition have been analysed between the 749 





significant differences in body mass and body fat (17.7 ± 2.5 % vs 17.8 ± 2.2 % 751 
respectively). Similar non-significant differences were reported by Lebrun et al. (1995), 752 
with a body mass of 59.5 ± 1.7 kg vs 59.5 ± 1.8 kg, and a body fat of 17.4 ± 1.2 % vs 17.3 753 
± 0.9 %. Furthermore, Abdollahpor et al. (2013), Beidleman et al. (1999) and De Souza et 754 
al. (1990) also reported non-significant results between the early-follicular and mid-755 
luteal sub-phases. Lebrun et al. (1995) reported that the MC sub-phases affects fluid 756 
retention, which in turn affects body mass and composition. However, Lebrun et al. 757 
(1995) also reported that regular exercise might reduce this effect, and therefore may 758 
help explain why no differences in body mass or composition were found between MC 759 
sub-phases. 760 
Furthermore, a number of studies made a comparison between phases, without 761 
specifying the sub-phases analysed, and reported non-significant differences in body 762 
mass and/or body composition (Giacomoni et al., 2000; Miskec, Potteiger, Nau, & Zebas, 763 
1997; Tsampoukos et al., 2010; Vaiksaar et al., 2011). Miskec et al. (1997) reported that 764 
differences in body mass might be due to water gains associated with an increase in 765 
progesterone and oestrogen. However, no differences were reported by the authors, 766 
and therefore the effects of the hormones might not be enough to be statistically 767 
relevant. 768 
In conclusion, from the available literature, it appears that the hormonal fluctuations 769 
during the MC do not influence body mass or body composition. This could be due to 770 
fluid regulation not being affected by the MC, as previously hypothesised by Janse de 771 
Jonge (2003), or due to the fact that the effects of the MC on fluid regulation might not 772 
be enough to impact body mass and body composition. Furthermore, it is possible that 773 
the differences in body composition and body mass occur in sub-phases that have not 774 
been compared previously, and therefore remain unknown. Further research involving 775 





2.6 Menstrual cycle physiology 777 
2.6.1 Heart Rate 778 
Heart Rate (HR) is an important parameter often monitored during exercise to determine 779 
exercise intensity, the status of the autonomic nervous system and cardiovascular fitness 780 
(Pestana et al., 2017; Schneider et al., 2018). As progesterone has been found to increase 781 
heart rate, it is plausible to assume that a higher HR would be found during the luteal 782 
phase, where the concentrations of progesterone are the highest throughout the MC 783 
(Pivarnik et al., 1992; Sedlak et al., 2012). The higher HR during the luteal phase has been 784 
explained by a possible decrease in plasma volume (Pivarnik et al., 1992), an increased 785 
capillary permeability (Pivarnik et al., 1992), an enhanced sympathetic activity (Pestana 786 
et al., 2017) and/or a direct effect of temperature on the sinoatrial node (Janse de Jonge, 787 
Thompson, Chuter, Silk, & Thom, 2012). 788 
The differences in HR have been studied between the early-follicular and mid-luteal sub-789 
phases, with non-significant results being reported by Bemben et al. (1995) and Dean et 790 
al. (2003) during a running and cycling incremental exercise to exhaustion, respectively. 791 
Other non-significant results between the early-follicular and mid-luteal sub-phases 792 
during exercise have also been reported by Abdollahpor et al. (2013), De Souza et al. 793 
(1990), Lebrun et al. (1995), Beidleman et al. (1999), and Oosthuyse et al. (2005). 794 
However, a significant difference was found by Janse de Jonge et al. (2012), who 795 
reported a higher resting HR during the mid-luteal (72 ± 5 bpm) compared to the early-796 
follicular sub-phase (68 ± 6 bpm). Interestingly, significant differences disappeared 797 
during an incremental cycling test to exhaustion (182 ± 16 bpm vs 182 ± 12 bpm). 798 
Furthermore, Janse de Jonge et al. (2012) did not report any significant differences 799 
during 60-minutes of submaximal exercise at 60% of V̇O2max, but no exact results were 800 
provided in the study. Janse de Jonge et al. (2012) suggested that the change in body 801 





possible that no differences were found at exhaustion because other factors might out-803 
weigh the effect of the temperature on HR. However, it is not clear what the other 60% 804 
refers to, as the authors did not provide further explanations. Except for the study by 805 
Janse de Jonge et al. (2012) who reported a significant difference in resting HR between 806 
the early-follicular and mid-luteal sub-phases, there is a unanimous consensus that 807 
exercise HR is not influenced by these two MC sub-phases regardless of the different 808 
methodologies implemented. 809 
The mid-luteal sub-phase has also been compared with the mid-follicular phase by 810 
Gordon et al. (2018) who reported non-significant differences during incremental cycling 811 
exercise to exhaustion. Furthermore, Hackney et al. (1991) found non-significant results 812 
during 60-minutes of cycling exercise at 70% of V̇O2max at different time points. 813 
Conversely, Pivarnik et al. (1992) reported opposite results, even though the testing 814 
protocol was very similar to the one used by (Hackney, Curley, & Nicklas, 1991). In fact, 815 
Pivarnik et al. (1992) reported a significantly higher HR at all time points (10, 20, 30, 40, 816 
50 and 60 minutes) during 60-minutes of exercise at 65-70% of V̇O2max, with an average 817 
10 bpm higher during the mid-luteal sub-phase. Other non-significant results between 818 
the mid-follicular and mid-luteal sub-phases have been reported by Jurkowski et al. 819 
(1981), Dombovy et al. (1987), Mattu et al. (2019), Dean et al. (2003) and Sunderland & 820 
Nevill (2003) across a range of exercise modalities and intensities in participants of 821 
varying sporting backgrounds. 822 
While some sub-phases have been studied quite well in relation to HR differences, 823 
studies on HR comparisons between specific sub-phases, such as mid-follicular and late-824 
luteal or late- and early-follicular sub phases are limited. For example, the differences in 825 
HR between the mid-follicular and late-luteal sub-phases have been tested only by 826 
Pestana et al. (2017), which compared Wingate anaerobic test results and reported 827 





respectively) but not in resting HR (73.43 ± 12.37 bpm vs 76.1 ± 12.33 bpm). Non-829 
significant results were also reported by Bemben et al. (1995) during a running 830 
incremental exercise to exhaustion between the late-follicular and the early-follicular 831 
sub-phases and between the late-follicular and the mid-luteal one. In agreement, Dean 832 
et al. (2003) also reported non-significant differences during an incremental cycling 833 
exercise to exhaustion between the early-follicular sub-phase and the mid-follicular sub-834 
phase.  835 
There are also a few studies that generically compared the luteal and follicular phases, 836 
but did not specify the sub-phases (De Bruyn-Prevost, Masset, & Sturbois, 1984; Köse, 837 
2018; Redman et al., 2003; Smekal et al., 2007; Stephenson, Kolka, & Wilkerson, 1982; 838 
Vaiksaar et al., 2011). In these studies, all authors reported non-significant differences 839 
between the luteal and follicular phases across different tests, including incremental 840 
tests to exhaustion, submaximal exercise, and Wingate anaerobic test in both non-active 841 
and active participants. 842 
In conclusion, it seems that the hormonal fluctuations during the MC phases do not 843 
impact the heart rate, independently of the protocol used. A possible explanation to this 844 
has been provided by Janse de Jonge et al. (2012) who stated that the difference in 845 
temperature between phases might be too low to significantly affect differences in HR, 846 
while other factors affecting HR have not been analysed or reported previously. 847 
2.6.2 Blood lactate 848 
Blood lactate is another important parameter commonly measured during both 849 
performance and clinical exercise testing to determine exercise intensity (Goodwin, 850 
Harris, Hernández, & Gladden, 2007). It has been hypothesised that a higher utilisation 851 
of fat during the mid-luteal sub-phase should be supported by a lower concentration of 852 





(Mattu et al., 2019; Redman et al., 2003). However, the current literature seems to 854 
contrast this hypothesis as majority of previous studies reported non-significant 855 
differences in blood lactate. 856 
The differences in blood lactate have been tested between the mid-follicular and mid-857 
luteal sub-phases, and the majority of the papers (9 out of 11) reported non-significant 858 
results. For example, Shaharudin et al. (2011) reported no differences between the mid-859 
follicular and mid-luteal sub-phases at rest and after the last sprint during a set of 3 860 
sprints at 120% V̇O2max, with 20 minutes of recovery. Similarly, Dean et al. (2003) 861 
reported no differences at rest and at the end of an incremental cycling exercise to 862 
exhaustion with moderately active participants. Moreover, Dombovy et al. (1987), 863 
Nicklas et al. (1989), Sunderland & Nevill (2003), Gurd et al. (2007), Wiecek et al. (2016), 864 
Gordon et al. (2018) and Mattu et al. (2019) all reported non-significant differences 865 
between the mid-follicular and mid-luteal sub-phases. Even though it has been 866 
speculated that oestrogen can increase lipid oxidation and spare glycogen, causing a 867 
decreased lactate response, the findings from Shaharudin et al. (2011) study showed no 868 
differences in lactate response to exercise during MC phases. 869 
However, in contrast with these findings, Jurkowski et al. (1981) and McCracken et al. 870 
(1994) reported higher lactate during the mid-follicular than the mid-luteal sub-phases. 871 
Jurkowski et al. (1981) reported a higher lactate during the mid-follicular than the mid-872 
luteal after 20-minutes of exercise at 66% of maximum power output (6.62 ± 0.8 mmol·l-873 
1 vs 4.92 ± 2.5 mmol·l-1), and 20-minutes of exercise at 90% of maximum power output 874 
(8.12 ± 0.9 mmol·l-1 vs 6.76 ± 0.6 mmol·l-1), but no differences after 20-minutes of 875 
exercise at 33% of maximum power output. McCracken et al. (1994) also reported a 876 
higher lactate during the mid-follicular sub-phase than the mid-luteal when measured 3 877 
minutes post-exercise (8.7 ± 1.8 mmol·l-1 vs 5.4 ± 1.2 mmol·l-1 respectively) as well as 30 878 





incremental exercise to exhaustion. However, McCracken et al. (1994) did not report any 880 
differences at rest (1.6 ± 0.2 mmol·l-1 vs 1.7 ± 0.3 mmol·l-1 respectively). Jurkowski et al. 881 
(1981) reported that these differences in lactate production may be due to factors 882 
influencing energy substrates and/or glycolytic enzymes. However, McCracken et al. 883 
(1994) reported that even though their data were not enough to provide an explanation, 884 
it is possible that the differences in lactate was due to a preferential metabolism of lipid 885 
associated with oestrogen that reduced the carbohydrate utilisation and the glycolytic 886 
activity. Even though contrasting results have been reported between the mid-luteal and 887 
mid-follicular sub-phases, the differences do not appear to be related to the participant’s 888 
level, the exercise modality, the test chosen or the modality to determine the MC sub-889 
phases.  890 
The mid-luteal sub-phase has also been compared with the early-follicular sub-phase, 891 
but no significant results were reported. Lamont (1986) reported no differences during 892 
a 60-minutes cycling exercise at 70% of V̇O2max but did not provide any numeric values. 893 
In agreement with the findings by Lamont (1986), Abdollahpor et al. (2013), Dean et al. 894 
(2003), Bemben et al. (1995) and De Souza et al. (1990) also reported non-significant 895 
differences between these two sub-phases. Dean et al. (2003) concluded that the MC 896 
effects on lactate might be hidden by the exercise-related increase in lactate levels. The 897 
increase in lactate due to the exercise would be higher than any difference caused by 898 
the MC, therefore possibly hiding its effect. 899 
Other sub-phases have been analysed only in a few studies. For example, a comparison 900 
between the early-follicular and the mid-follicular sub-phases has been made by Dean 901 
et al. (2003) who reported non-significant differences both at rest and at the end of the 902 
exercise. Similarly, no differences were reported between the early-follicular and the 903 
late-follicular sub-phases by Bemben et al. (1995) at rest and post-exercise. Bemben et 904 





sub-phases and reported non-significant differences. Non-significant results have also 906 
been reported between the late-luteal and the mid-follicular sub-phases by Middleton 907 
& Wenger (2006) and Stefanovsky et al. (2016). 908 
A relatively high number of papers compared the luteal and follicular phases but did not 909 
specify the sub-phases, and therefore these results should be considered with caution 910 
due to fact that different sub-phases with different hormonal concentrations might have 911 
been compared. Whilst De Bruyn-Prevost et al. (1984), Miskec et al. (1997), Smekal et 912 
al. (2007), Tsampoukos et al. (2011) and Vaiksaar et al. (2011) did not report any 913 
significant differences between those two phases, Redman et al. (2003) found significant 914 
differences between the luteal and follicular phases. Specifically, Redman et al. (2003) 915 
showed a significantly lower lactate concentration in the luteal phase during a steady 916 
state cycling exercise of 20 minutes at 25% V̇O2max followed by 20 minutes at 75% of 917 
V̇O2max, however, exact values related to lactate levels were not provided. Therefore, 918 
the different results might be explained by the lack of sub-phase determination, which 919 
can lead to testing the participants under different hormonal conditions whilst 920 
considering them in the same phase. As both progesterone and oestrogen 921 
concentrations fluctuate during a single MC phase, the determination of sub-phases is 922 
necessary to provide more certainty that the participants are being tested during the 923 
same sub-phases. 924 
The results from Jurkowski et al. (1981), McCracken et al. (1994) and Redman et al. 925 
(2003) showed a lower lactate concentration during the luteal phase, which might 926 
suggest a reduction of carbohydrate metabolised during this phase. However, when the 927 
overall results from the current literature are considered it appears that the MC phases 928 
do not influence the lactate production, thus suggesting no differences in the 929 
contributions of adenosine triphosphate (ATP) production between follicular and luteal 930 





2.6.3 Maximal oxygen consumption 932 
Maximal oxygen consumption (V̇O2max) is defined as the highest rate of oxygen uptake 933 
and consumption by the body, during a maximal exercise (Poole, Wilkerson, & Jones, 934 
2008). It is widely considered the gold standard measure of cardiovascular fitness and 935 
exercise capacity (Koutlianos et al., 2013), but it is also an important parameter for 936 
repeated sprint ability, as it affects the recovery between sprints and the ability to 937 
maintain a high performance when fatigue arises (Aguiar et al., 2016; Aziz et al., 2000; 938 
Jones et al., 2013; Sanders et al., 2017). Abdollahpor et al. (2013) hypothesised that 939 
V̇O2max might be lower during the luteal phase because the minute ventilation would 940 
be higher due to progesterone’s effect on ventilation (V̇e). The increased minute 941 
ventilation, and therefore the higher oxygen cost, would utilise a higher portion of 942 
V̇O2max that might limit maximal exercise performance (Vella, Marks, & Robergs, 2006). 943 
Janse de Jonge (2003) reported that V̇O2max might be affected by the MC if its 944 
determinants, such as blood lactate, body mass and heart rate, would be affected by it. 945 
However, as blood lactate, body mass and heart rate are not influenced by the menstrual 946 
phases it is also speculated that MC would not affect V̇O2max (Janse de Jonge, 2003).  947 
The differences in V̇O2max have been tested between the mid-luteal and the early-948 
follicular sub-phases by different authors, and no significant results have been reported. 949 
Beidleman et al. (1999) and De Souza et al. (1990) reported non-significant differences 950 
in V̇O2max during an incremental running exercise to exhaustion. Furthermore, other 951 
non-significant results were reported by Lebrun et al. (1995), Abdollahpor et al. (2013), 952 
Bemben et al. (1995), Dean et al. (2003), and Janse de Jonge et al. (2012). 953 
The mid-luteal sub-phase was also compared with the mid-follicular sub-phase by Dean 954 
et al. (2003), Gordon et al. (2018), Mattu et al. (2019) and Dombovy et al. (1987) with all 955 
studies reporting non-significant differences in V̇O2max. Dean et al. (2003), Gordon et al. 956 





using different determination methods (Table 1). In contrast, Schoene et al. (1981) 958 
reported a lower V̇O2max during the mid-luteal sub-phase (29.3 ± 4.2 ml·kg1·min-1) when 959 
compared with the mid-follicular (33.6 ± 2.7 ml·kg1·min-1) in non-active participants 960 
during an incremental cycling exercise to exhaustion. However, Schoene et al. (1981) 961 
could not find significant differences in the active participants group (48.6 ± 2.2 962 
ml·kg1·min-1 vs 48.1 ± 2.6 ml·kg1·min-1 respectively). The authors provided an explanation 963 
stating that the active participants, due to their experience, might be able to tolerate 964 
subjective/personal factors that influence motivation and be driven to perform well in 965 
any circumstances, and therefore be less susceptible to MC effects (Schoene et al., 966 
1981). 967 
Other sub-phases have been compared by Bemben et al. (1995) that reported non-968 
significant results between the late-follicular with both the early-follicular and the mid-969 
luteal. Moreover, non-significant differences were also found between the early-970 
follicular and the mid-follicular sub-phases (Dean, Perreault, Mazzeo, & Horton, 2003), 971 
and between the early-follicular and late-luteal ones during a 20m running shuttle test 972 
(Lamina, Hanif, & Muhammed, 2011). Furthermore, a number of studies compared the 973 
follicular and luteal phases and reported non-significant results, but failed to mention 974 
the exact sub-phases (De Bruyn-Prevost et al., 1984; Redman et al., 2003; Smekal et al., 975 
2007; Stephenson et al., 1982; Vaiksaar et al., 2011). Based on the current literature, 976 
regardless of the exercise modality, the tests or the procedures, there seems to be a 977 
general consensus that V̇O2max is not affected by the MC phases (Gordon et al., 2018; 978 
Jurkowski, Jones, Toews, & Sutton, 1981). 979 
2.6.4 Respiratory Exchange Ratio 980 
Whilst V̇O2 can be analysed independently, it is also used to calculate the respiratory 981 
exchange ratio (RER). The RER is the ratio between the carbon dioxide production and 982 





the expenditure of energy (Ramos-Jiménez et al., 2008). The RER can range from 0.7, 984 
which is the ratio between carbon dioxide production and the oxygen usage during the 985 
oxidation of a molecule of fatty acid and go above 1.0, where 1.0 the ratio from the 986 
oxidation of a molecule of carbohydrate (Nilsson, Björnson, Flockhart, Larsen, & Nielsen, 987 
2019). When the RER goes above 1.0, it means that the production of CO2 is coming from 988 
a different source, non-related to the oxidation of fatty acids or carbohydrates, such as 989 
hyperventilation (Péronnet & Aguilaniu, 2006). The respiratory exchange ratio has been 990 
shown to be correlated with other fitness variables such as maximum HR, V̇O2max and 991 
lactate threshold (Ramos-Jiménez et al., 2008), and it has been hypothesised that a 992 
higher utilisation of fat during the luteal phase would be confirmed by a lower RER (Bunt, 993 
1990; Nicklas et al., 1989; Redman et al., 2003).  994 
The effects of the mid-luteal and early-follicular sub-phases on RER have been analysed, 995 
but no significant results have been reported by Dean et al. (2003), Lamont (1986), De 996 
Souza et al. (1990), Janse de Jonge et al. (2012), Lebrun et al. (1995) and Oosthuyse et 997 
al. (2005). As RER is a ratio between V̇O2 and carbon dioxide production (V̇CO2), an 998 
explanation can be provided by the fact that Dean et al. (2003), De Souza et al. (1990) 999 
and Janse de Jonge et al. (2012) reported non-significant differences in V̇O2 and/or V̇CO2 1000 
between the MC phases. For this reason, it is plausible to believe that the ratio was also 1001 
unchanged by the MC phases. 1002 
The RER has also been analysed between the mid-luteal and the mid-follicular sub-1003 
phases, and no significant differences have been shown by Hackney et al. (1991) and 1004 
Gordon et al. (2018). Further non-significant results between the mid-luteal and mid-1005 
follicular sub-phases were also found by Dean et al. (2003), Nicklas et al. (1989), Gurd et 1006 
al. (2007) and Mattu et al. (2019). 1007 
Moreover, the mid-follicular sub-phase has also been used as a comparison with the 1008 





Furthermore, a significantly lower RER has been found in the late-luteal sub-phase (1.17 1010 
± 0.06) when compared with the mid-follicular one (1.19 ± 0.06) by Middleton & Wenger 1011 
(2006) in the only study about the effects of the MC on RSA in literature, during a cycling 1012 
RSA protocol of 10 sprints of 6 seconds each. 1013 
Oosthuyse et al. (2005) reported non-significant results between the late-follicular, 1014 
early-follicular and mid-luteal sub-phases. Smekal et al. (2007) and Vaiksaar et al. (2011) 1015 
compared the follicular and luteal phases, without mentioning the sub-phase, and 1016 
reported non-significant differences. The findings from Smekal et al. (2007) and Vaiksaar 1017 
et al. (2011) can be explained by the fact that they did not analyse specific sub-phases, 1018 
and therefore they might have included data from different sub-phases, and therefore 1019 
different hormonal concentrations. As their aim was to compare MC phases because of 1020 
their different hormonal concentrations, by including unspecified sub-phases and 1021 
therefore mixing different hormonal concentrations together, they might have affected 1022 
the results. In contrast, Redman et al. (2003) reported a lower RER during the luteal 1023 
phase following incremental cycling exercise to exhaustion than during the follicular one 1024 
(1.05 ± 0.03 vs 1.16 ± 0.04 respectively), but no effects at rest (0.88 ± 0.03 vs 0.9 ± 0.03 1025 
respectively). The same study by Redman et al. (2003) also reported lower RER during 1026 
the luteal phase during submaximal exercises at 25% and 75% V̇O2max but did not 1027 
actually provide the results. From the current literature it appears that the MC does not 1028 
affect RER, contrasting the hypothesis of a change in energy supply during exercise 1029 
(Vaiksaar et al., 2011) and suggesting no changes in fat metabolism and fuel oxidation 1030 
between phases (Gurd et al., 2007; Smekal et al., 2007). 1031 
2.6.5 Minute Ventilation 1032 
Minute ventilation (V̇e) has been defined as the volume of gas inhaled or exhaled from 1033 
a person's lungs per minute and it is the product between breathing frequency and tidal 1034 





ventilation increases during exercise to meet a higher demand for O2 uptake and CO2 1036 
elimination, V̇e is considered an important physiological parameter to analyse (Forster, 1037 
Haouzi, & Dempsey, 2012). V̇e has been shown to be stimulated by progesterone, and 1038 
therefore it would be expected to see a higher V̇e during the mid-luteal sub-phase, when 1039 
the progesterone is the highest throughout the MC (Beidleman et al., 1999; De Souza et 1040 
al., 1990; Schoene, Robertson, Pierson, & Peterson, 1981; Williams & Krahenbuhl, 1997). 1041 
However, V̇e does not appear to change significantly between MC phases. The most 1042 
studied sub-phase in relation to V̇e has been the mid-luteal, which has been compared 1043 
with the early-follicular. Non-significant differences in V̇e between the mid-luteal and 1044 
the early-follicular sub-phase have been reported by Bemben et al. (1995), Lamont 1045 
(1986), De Souza et al. (1990), Lebrun et al. (1995), and Beidleman et al. (1999). An 1046 
explanation has been provided by Beidleman et al. (1999) who suggested that other 1047 
factors (i.e., central motor command; reflexes from the exercising limb) might impact 1048 
ventilation to a greater extent than progesterone. In contrast, Williams & Krahenbuhl 1049 
(1997) reported a significantly higher V̇e during the mid-luteal sub-phase than the early-1050 
follicular at rest (12.4 0.7 l·min-1 vs 10.3 0.8 l·min-1 respectively), at 55% V̇O2max (46.2 ± 1051 
0.9 l·min-1 vs 42.2 ± 1.4 l·min-1 respectively) and at 80% V̇O2max (68.8 ± 3 l·min-1 vs 63.6 1052 
± 2 l·min-1 respectively), which is in agreement with the hypothesis of progesterone 1053 
affecting V̇e. Williams & Krahenbuhl (1997) also analysed and compared the late-1054 
follicular, early-luteal and late-luteal sub-phases, but no other differences were 1055 
reported. As progesterone peaks during the mid-luteal sub-phase, a lack of significant 1056 
differences between other phases can be explained by the fact that progesterone might 1057 
have been too low to affect ventilation significantly (Williams & Krahenbuhl, 1997).  1058 
The mid-luteal sub-phase has also been compared with the mid-follicular, and the 1059 
majority of the authors did not report any significant differences (Dombovy, Bonekat, 1060 
Williams, & Staats, 1987; Gordon et al., 2018; Hackney et al., 1991; Jurkowski et al., 1981; 1061 





rest in the mid-luteal sub-phase, when compared with the mid-follicular one in active 1063 
participants (10.7 ± 0.7 l·min-1 vs 8.8 ± 0.6 l·min-1 respectively) and non-active 1064 
participants (10 ± 0.7 l·min-1 vs 7.7 ± 0.9 l·min-1 respectively). The authors suggested that 1065 
these findings are due to progesterone that, through a central mechanism, increases 1066 
ventilation (Schoene et al., 1981). 1067 
The follicular and luteal phases were also compared without specifying the sub-phases, 1068 
but no significant results were reported by Redman et al. (2003) during an incremental 1069 
cycling exercise to exhaustion in non-active participants. Similarly, Vaiksaar et al. (2011) 1070 
reported non-significant result in an incremental cycling exercise to exhaustion, but with 1071 
active participants. Furthermore, Smekal et al. (2007) also reported non-significant 1072 
results in an incremental rowing exercise to exhaustion, with active participants. These 1073 
3 studies found the same results regardless of the participants’ level and background, 1074 
and regardless the testing modality, reinforcing the conclusions that the MC hormonal 1075 
fluctuations do not influence V̇e. Smekal et al. (2007) suggested that even though 1076 
changes in body temperature and progesterone might affect V̇e, no significant 1077 
differences have been seen between different phases of the menstrual cycle. This is 1078 
consistent with what Janse de Jonge et al. (2012) reported, that the differences in 1079 
temperature between different sub-phases might be too low to significantly impact 1080 
physiological parameters. 1081 
In conclusion, minute ventilation does not seem to be influenced by the MC phases. 1082 
However, due to the multiple possible explanations provided by different authors, more 1083 
studies are required to understand how all these factors interact with the menstrual 1084 







2.7 Perceptual measures 1088 
Whilst physiological factors are fundamental in understanding sport performance, 1089 
perceptual measures are also important in doing so, as they can provide a measure of 1090 
how the athlete feels during an exercise (Williams, 2017). The rating of perceived 1091 
exertion (RPE) can be used as a simplified measure of physiological and performance 1092 
indices, and to monitor exercise intensity and load (Halperin & Emanuel, 2019). There 1093 
are clear advantages to using RPE, such as the easiness of use and the requirement for 1094 
any material, however there are limitations that threaten the validity of RPE scales. Some 1095 
of these limitations include different definitions, instructions and administration 1096 
strategies (Halperin & Emanuel, 2019), and therefore the results should be taken with 1097 
caution. 1098 
Due to the lack of published data available it is currently not clear whether the MC does 1099 
or does not affect RPE. The current literature on the effects of MC phases on RPE also 1100 
makes a limited attempt to explain the potential mechanisms behind the findings. It has 1101 
been hypothesised by Abdollahpor et al. (2013) and Stephenson et al. (1982) that no 1102 
differences in RPE would be found because the MC does not have effect on physiological 1103 
or performances parameters, such as V̇O2, HR or the time to exhaustion. However, as it 1104 
has been shown that RPE is influenced by circadian rhythmicity, it is plausible that RPE 1105 
could be influenced by the MC rhythmicity (Florida-James, Wallymahmed, & Reilly, 1996; 1106 
Vitale, La Torre, Baldassarre, Piacentini, & Bonato, 2017). As RPE might change during 1107 
the day, comparing two testing sessions during different moments of the day might show 1108 
a difference in RPE that is only due to the daily variations and not due to the menstrual 1109 
cycle. Furthermore, progesterone and oestrogen are also affected by the circadian 1110 
rhythm, and their concentrations fluctuate during the same day (Janse de Jonge, 2003; 1111 
Vaiksaar et al., 2011). The complexity generated by having multiple biological rhythms 1112 





more data are needed to better understand the relationship between RPE, the 1114 
menstrual cycle and circadian rhythms.  1115 
In the few papers that analysed RPE responses, Hackney et al. (1991), Sunderland & 1116 
Nevill (2003), Dombovy et al. (1987) and Nicklas et al. (1989) reported no significant 1117 
differences between mid-luteal and mid-follicular sub-phases. In contrast, significant 1118 
differences were reported between the mid-follicular (6.2 ± 1.5) and mid-luteal (5.3 ± 1119 
1.4) sub-phases by Mattu et al. (2019), using a 0-10 Borg scale, during a 30 minute 1120 
constant load exercise at maximal lactate steady-state power. Conversely, Pivarnik et al. 1121 
(1992) reported a higher RPE during the mid-luteal sub-phase than during the mid-1122 
follicular, but only after 50 minutes of exercise. Pivarnik et al. (1992) concluded that the 1123 
higher RPE was related to the inability to achieve thermal equilibrium when exercising 1124 
during the luteal phase. In fact, during the luteal phase Pivarnik et al. (1992) reported an 1125 
increase in rectal temperature, but not in sweat loss. 1126 
However, Mattu et al. (2019) reported opposite conclusions and explained the lower RPE 1127 
during the luteal phase by a decreased perception in pain typical of the luteal phase, 1128 
known as “luteal analgesia effect”. These conclusions from Mattu et al. (2019) link with 1129 
hypothesis of a decrease in pain modulated by oestrogen, as reported by Hooper et al. 1130 
(2011). However, as oestrogen peaks at the end of the follicular phase, but also in the 1131 
middle of the luteal phase, it is not clear which phase would be influenced the most. In 1132 
order to better understand the effects of oestrogen, pain modulation and RPE, the two 1133 
sub-phases where the oestrogen is at its top (late-follicular and mid-luteal) should be 1134 
analysed and compared with every other sub-phase. 1135 
Non-significant differences were also reported between the mid-luteal and early-1136 
follicular sub-phases by Beidleman et al. (1999), Abdollahpor et al. (2013), and De Souza 1137 





the early-follicular and mid-luteal sub-phases at different times of a 60-minutes exercise 1139 
at 60% of V̇O2max. 1140 
Significant differences were also found by Hooper et al. (2011) that reported a higher 1141 
RPE during the early-follicular (13.46 ± 1.46) when compared with both the late-follicular 1142 
(13.03 ± 1.32) and the luteal phase (12.62 ± 1.5). Hooper et al. (2011) reported that the 1143 
higher RPE occurred when a higher pain score was reported, that might have influenced 1144 
the perceived exertion. Other papers focused on unspecified sub-phases, but did not 1145 
provide the values (Cristina-Souza et al., 2019; Miskec et al., 1997; Stephenson et al., 1146 
1982). 1147 
Unfortunately, Dombovy et al. (1987), Nicklas et al. (1989), De Souza et al. (1990), 1148 
Hackney et al. (1991), Beidleman et al. (1999) and Sunderland & Nevill (2003) did not 1149 
provide any attempt to explain why they could or could not find differences in RPE 1150 
between sub-phases, or were uncertain/unable to provide one. The literature is not clear 1151 
and is not in agreement on how RPE is affected by the menstrual cycle phases, and 1152 
different authors provided different explanations to justify their results. It appears that 1153 
both a lower and a higher RPE during the luteal phase, compared with the follicular 1154 
phase can be justified by a number of different mechanisms (i.e. pain, luteal analgesia 1155 
effect, thermal equilibrium), but the exact mechanism behind the findings remains 1156 
largely unknown. However, the lack of reported differences in RPE scores between the 1157 
MC phases may be explained through its strong correlation with the previously 1158 
mentioned physiological parameters and their lack of differences between MC phases 1159 








2.8 Effects of hormones on sports performance 1164 
Interestingly, the majority of aforementioned studies (32 out of 43) were conducted 1165 
using aerobic exercises, with very little focus on anaerobic exercise. Currently, only 1166 
Giacomoni et al. (2000), Middleton & Wenger (2006) and Julian et al. (2017) analysed a 1167 
performance shorter than 10 seconds, showing a lack of available data in short duration, 1168 
high intensity exercise that can be associated with team sport performance (Bishop & 1169 
Girard, 2013; Middleton & Wenger, 2006). These three papers all analysed multiple 1170 
sprints, but with different protocols and different modalities, reducing the possibility of 1171 
a direct comparison of results. 1172 
Giacomoni et al. (2000) analysed the differences between the mid-follicular and mid-1173 
luteal sub-phases when performing 4 cycling sprints of 8 seconds each, with 3 minutes 1174 
recovery. Giacomoni et al. (2000) reported no differences in maximal cycling power, but 1175 
no explanation was provided. Middleton & Wenger (2006) compared the mid-follicular 1176 
and late-luteal sub-phases in active participants performing 10 sprints 6 seconds each, 1177 
with 30 seconds recovery. Similar to Giacomoni et al. (2000), no differences in peak 1178 
power were reported. However, the average work during the sprints was higher during 1179 
the late-luteal sub-phase than the mid-follicular. Middleton & Wenger (2006) explained 1180 
the higher work during the late-luteal sub-phase was due to higher PCr and ATP stores, 1181 
caused by high oestrogen, which sustains the performance throughout subsequent 1182 
sprints. Furthermore, the authors calculated that the difference in work between the 1183 
two phases would translate in approximately 1 meter difference during a 6-seconds 1184 
sprint, which could make the difference during a performance (Middleton & Wenger, 1185 
2006). More recently, Julian et al. (2017) recruited active participants to perform 3 1186 
sprints of 30 meters each, with 2 minutes recovery, and compared the results between 1187 
the early-follicular and mid-luteal sub-phases. They reported non-significant differences 1188 





al. (2017) suggested that a higher basal body temperature might improve sprinting 1190 
performance, but also reported that this hypothesis has found contrasting results and 1191 
opinions in previous literature. If this hypothesis were to be true, and considering that 1192 
basal body temperature changes throughout the cycle, a higher sprinting performance 1193 
would be expected during the mid-luteal sub-phase than the early-follicular because of 1194 
its higher basal body temperature. However, as no differences were reported, the 1195 
hypothesis does not seem to hold, and it could be because the changes in basal body 1196 
temperature between the two sub-phases of the MC are too small to significantly affect 1197 
sprinting performance. 1198 
In conclusion, it appears that the MC sub-phases do not influence repeated sprints 1199 
performance as measured by peak power or time, but may influence the average work 1200 
throughout the sprints. However, due to the lack of studies on this kind of performance, 1201 
drawing conclusions would be premature.  1202 
2.9 Repeated Sprint Ability 1203 
After defining RSA as the ability to perform repeated sprints with a short, incomplete 1204 
recovery between repetitions, Bishop et al. (2011) further described specific 1205 
characteristics of RSA exercises. Sprints have to last less than 10 seconds each, where 1206 
maximal workout can be nearly maintained until the end of the exercise, and the 1207 
recovery has to be less than 60 seconds long (Bishop et al., 2011). In order to study and 1208 
analyse an RSA performance, is important to determine physiological and metabolic 1209 
factors affecting it. 1210 
2.9.1 Aerobic and anaerobic factors 1211 
The contributing factors to RSA have been studied by different authors that tried to 1212 
identify aerobic and anaerobic parameters that might be important for RSA performance 1213 





Haj-Sassi, Chamari, & Souissi, 2015; Jones et al., 2013; Pyne, Saunders, Montgomery, 1215 
Hewitt, & Sheehan, 2008; Sanders et al., 2017; Thébault, Léger, & Passelergue, 2011). 1216 
When trying to determine the importance of aerobic fitness for RSA, a number of studies 1217 
were analysed and provided evidence showing a significant relationship between 1218 
V̇O2max and parameters that reflect RSA performance such as total sprint time (Aziz et 1219 
al., 2000; Jones et al., 2013; Sanders et al., 2017), average sprint time (Jones et al., 2013; 1220 
Sanders et al., 2017), and fatigue indexes (Aguiar et al., 2016). 1221 
V̇O2max does not directly affect the single sprinting performance, but rather helps with 1222 
the recovery between sprints, as has been clearly shown for V̇O2 kinetics (Buchheit, 1223 
2012; Dupont, McCall, Prieur, Millet, & Berthoin, 2010) allowing to maintain a higher 1224 
performance throughout subsequent sprints (Aguiar et al., 2016; Aziz et al., 2000; Jones 1225 
et al., 2013; Sanders et al., 2017). The advantages of a better recovery seem to be related 1226 
to the ability to restore PCr and ATP, and tolerate, remove and buffer hydrogen ions 1227 
from the active muscles (Aguiar et al., 2016; Aziz et al., 2000; Jones et al., 2013; Sanders 1228 
et al., 2017). 1229 
However, some contrasting results have been shown by other authors in regards of the 1230 
importance of V̇O2max, reporting no significant relationship with total sprint time 1231 
(Castagna et al., 2007; Pyne et al., 2008), power output (Bishop, Lawrence, & Spencer, 1232 
2003), power decrement (Bishop et al., 2003), total work (Bishop et al., 2003) or fatigue 1233 
indexes (Castagna et al., 2007). The contrasting results by Pyne et al. (2008) could be 1234 
explained by the fact that V̇O2max was estimated and not measured directly, thus 1235 
leaving the possibility of a wrong estimation and therefore the likelihood of different 1236 
results if a direct measurement was used instead. Bishop et al. (2003) and Castagna et 1237 
al. (2007) explained the lack of significance between V̇O2max and RSA performance due 1238 
to the short duration of the protocol and the recovery time, stating that V̇O2max might 1239 





to the organism to recover better, as a short recovery might not be enough to influence 1241 
PCr resynthesis.  1242 
Whilst the aerobic fitness contribution seems to be important, anaerobic parameters 1243 
and their relationship with RSA have also been analysed (Aguiar et al., 2016; Pyne et al., 1244 
2008). As a RSA performance indicator, total sprint time has been studied and has been 1245 
found to significantly correlate with anaerobic parameters such as the best sprint time 1246 
(Aguiar et al., 2016; Dupont et al., 2010), speed and acceleration (Pyne et al., 2008).  1247 
Aguiar et al. (2016) and Pyne et al. (2008) concluded that the strong correlation between 1248 
the best time, and therefore maximal velocity, and the RSA performance suggests that 1249 
one of the fundamental mechanisms responsible for RSA is the maximum ATP 1250 
production rate. Dupont et al. (2010), Aguiar et al. (2016) and Pyne et al. (2008) 1251 
suggested that, even though aerobic fitness might play a role for RSA performance, it is 1252 
the anaerobic components that influences the ability to repeat sprints the most. 1253 
Not every author agrees with the magnitude of the importance of aerobic or anaerobic 1254 
parameters for RSA, showing contradictory results (Aguiar et al., 2016; Gharbi et al., 1255 
2015; Sanders et al., 2017). These discrepancies could be due to different types of RSA 1256 
tests used (Sanders et al., 2017; Thébault et al., 2011), or the test used to assess aerobic 1257 
and anaerobic capacity (Gharbi et al., 2015; Thébault et al., 2011), that might have 1258 
influenced the outcome of a study. Nonetheless, based on the current literature it 1259 
appears that RSA performance is influenced by both aerobic and anaerobic fitness 1260 
parameters. Specifically, aerobic fitness seems to be more important to maintain the 1261 
performance throughout multiple sprints (Aguiar et al., 2016; Aziz et al., 2000; Jones et 1262 
al., 2013; Sanders et al., 2017), when the athlete is subjected to higher levels of fatigue, 1263 
and its importance appears to gradually increase with the number of repeated sprints. 1264 





therefore achieving better results (total time, best sprint time) (Aguiar et al., 2016; 1266 
Dupont et al., 2010; Pyne et al., 2008).  1267 
From the current literature it appears that the hormonal fluctuations during the MC do 1268 
not affect V̇O2max and/or speed and acceleration. This suggests that the influence from 1269 
both the aerobic and anaerobic parameters taken into consideration might not change 1270 
between different sub-phases of the MC, and therefore RSA performance may not be 1271 
influenced by the different phases. 1272 
2.9.2 Energy metabolism 1273 
As both aerobic and anaerobic factors related to RSA performance are dependent on 1274 
energy availability, it is important to understand the energy metabolism during a single 1275 
high-intensity sprint, but also changes in energy contribution as sprints are repeated 1276 
(Aguiar et al., 2016; A. Aziz et al., 2000; Gharbi et al., 2015). 1277 
2.9.2.1 Single sprint 1278 
PCr availability, anaerobic glycolysis and oxidative metabolism all have a role in providing 1279 
the energy necessary to perform a maximal sprint, but they contribute in different 1280 
proportions and their contribution changes throughout the sprint (Baker, McCormick, & 1281 
Robergs, 2010). At the beginning of an intense short exercise, all the energy mechanisms 1282 
are activated (Hargreaves & Spriet, 2020). However, PCr and anaerobic glycolysis can 1283 
provide ATP at a faster rate in comparison to aerobic pathways (Hargreaves & Spriet, 1284 
2020). In fact, PCr availability and anaerobic glycolysis seem to be the two most 1285 
important factors in a single maximal 6-s sprint, contributing ~45% and ~40% of the total 1286 
energy, respectively (Bishop, 2012; Dawson et al., 2007). A much smaller contribution 1287 
during a single short sprint is provided by the oxidative metabolism, which supplies 10% 1288 
of the total energy (Bishop, 2012). The relative energetic contribution during a maximal 1289 





Dawson, & Goodman, 2005). Longer sprints will result in a higher PCr depletion, as 1291 
shown by Spencer et al. (2005) that reported 40-70% depletion of PCr stores during a 1292 
10-12.5 seconds sprint, and 35-55% depletion during a 6 seconds sprint.  1293 
2.9.2.2 RSA 1294 
Energy contribution changes do not only occur during a single short sprint, but also with 1295 
repeated consecutive sprints. The contribution of different energy systems during a RSA 1296 
exercise appears to be largely influenced by sprint intensity, sprint duration, number of 1297 
sprints and recovery duration between sprints (Spencer et al., 2005). When the sprints 1298 
are repeated with a short recovery time that does not allow the replenishment of PCr 1299 
and ATP, it consequently changes the contribution of the energetic systems. It appears 1300 
that the contribution from glycolysis diminishes much more than the PCr, which 1301 
becomes predominant. Although the PCr absolute contribution decreases, when 1302 
compared with the glycolysis contribution, PCr raises to 80% of the total anaerobic ATP 1303 
production (Gaitanos, Williams, Boobis, & Brooks, 1993). This shows that the reliance on 1304 
PCr to produce ATP, compared to the glycolysis, increases with the number of 1305 
subsequent sprints. Similar conclusions have been drawn by Bishop (2012), who 1306 
demonstrated a link between PCr availability and RSA performance (Bishop, 2012). 1307 
Furthermore, Gaitanos et al. (1993) suggested that with repeated 6-s maximal sprints 1308 
cycling sprints the contribution of PCr and oxidative metabolism increases during the 1309 
latter sprints, whilst the anaerobic glycogenolysis becomes increasingly inhibited. In fact, 1310 
the contribution from the aerobic metabolism may increase to as much as 40% of the 1311 
total energy supply during the final sprints of repeated sprints protocol (Bishop, 2012).  1312 
Even though it has been demonstrated that oestrogen and progesterone can affect 1313 
energy metabolism, most of the studies were not able to report these differences, and 1314 





a RSA exercise. However, as running RSA in relation to the MC has never been tested 1316 
before, this is only an assumption based on previous studies on other tests and 1317 
performances.  1318 
2.9.3 Fatigue 1319 
Fatigue during RSA exercises is shown as a decrease in sprint speed, both maximal and 1320 
mean, and/or a decrease in peak power or total work over sprint repetitions (Girard, 1321 
Mendez-Villanueva, & Bishop, 2011; Sanders et al., 2017). A typical performance 1322 
decrement has been reported by Aziz et al. (2000), which reported a decrease in 1323 
performance (sprinting time) of 5.4% that confirms a previous report by Wadley & Le 1324 
Rossignol (1998) (5.5%). The fatigue develops after the first sprint, and it is caused by 1325 
different factors such as sprinting duration and recovery time, that contribute to its 1326 
timing and magnitude (Girard et al., 2011). Another aspect affecting fatigue is the 1327 
limitation in energy supply. Since during a RSA performance the recovery is incomplete, 1328 
the PCr cannot be completely restored before the following sprint, resulting in a lower 1329 
availability of PCr to restore the ATP for subsequent sprints, resulting in a lower 1330 
performance (Dawson et al., 2007; Gaitanos et al., 1993). Furthermore, hydrogen ion 1331 
accumulation occurring during RSA exercises may affect the sprinting performance 1332 
because of the inhibition on glycogen phosphorylase activity, causing a lower ATP 1333 
production from glycogenolysis (Girard et al., 2011; Spriet, Lindinger, McKelvie, 1334 
Heigenhauser, & Jones, 1989). Moreover, another important factor is the neural drive, 1335 
as the inability to fully activate the musculature can reduce the force production, and 1336 
therefore reduce the RSA performance (Girard et al., 2011). This mechanism has been 1337 
shown especially when the fatigue level is high (Fatigue Index or Sprint Decrement Score 1338 
higher than 10%) (Girard et al., 2011). 1339 
The rate at which fatigue develops seems to be mostly related to aerobic fitness, and 1340 





been correlated with the ability to clear hydrogen ions, delaying the fatigue and allowing 1342 
a better performance through subsequent sprints (Aguiar et al., 2016; Aziz et al., 2000; 1343 
Jones et al., 2013; Sanders et al., 2017). Girard et al. (2011) and Spriet et al. (1989) 1344 
explained that the mechanism by which hydrogen ions accumulate during RSA may 1345 
affect sprinting performance through the inhibition of ATP derived from glycolysis, and 1346 
adverse effects on the contractile apparatus. Bishop et al. (2003) also analysed the role 1347 
of V̇O2max in RSA performance, and were not able to report any significant relationship 1348 
between V̇O2max and fatigue. However, they reported a significant correlation between 1349 
power decrement and muscle pH, reporting that hydrogen ion accumulation may impair 1350 
RSA performance via inhibition of glycolysis, or negative effects with the contractile 1351 
process (Bishop et al., 2003). However, even though Aguiar et al. (2016), Gharbi et al. 1352 
(2015) and Bishop et al. (2003) reported that aerobic fitness is the major factor to 1353 
attenuate fatigue, Castagna et al. (2007) could not report the same conclusions. The lack 1354 
of relationship between fatigue and V̇O2max was justified by short recovery time, which 1355 
did not give enough time to the aerobic system to be relevant and influence recovery 1356 
(Castagna et al., 2007). 1357 
Other aspects have been studied and correlated with performance decrement during 1358 
RSA tests. For example, a higher performance in the initial sprint brings a higher 1359 
decrement in performance of the consecutive bouts, and this happens because a greater 1360 
initial sprint will have a greater effect in muscle metabolites (Bishop et al., 2003; Girard 1361 
et al., 2011; Hamilton, Nevill, Brooks, & Williams, 1991). Furthermore, as mentioned 1362 
earlier, one of the effects of hydrogen ion accumulation is the inhibition of glycolysis, 1363 
and therefore an important aspect to consider about fatigue is the limitation in energy 1364 
supply. Since during a RSA performance the recovery is incomplete, PCr cannot be 1365 
completely restored before the following sprint, resulting in a lower availability of PCr to 1366 
restore the ATP for subsequent sprints, causing a reduction in performance (Dawson et 1367 





V̇O2max, might not be affected by the MC, it appears that fatigue might also not be 1369 
affected by the MC and the hormonal fluctuations between sub-phases. 1370 
2.9.4 Fatigue indexes 1371 
Fatigue can be quantified by the use of a specific index called the Fatigue Index (FI), 1372 
which is calculated using the best and the worst sprinting times during the RSA exercise 1373 
(equation 1) (Girard et al., 2011). 1374 
𝐹𝐼 = 100 𝑥 (
𝑆𝑏𝑒𝑠𝑡−𝑆𝑤𝑜𝑟𝑠𝑡
𝑆𝑏𝑒𝑠𝑡
) (Eq. 1) 1375 
When looking at equation 1, S is used to indicate the sprint performance, and can be 1376 
used for speed, work or power based on the parameter and the type of performance 1377 
you are considering. However, this method is not considered as reliable and valid as the 1378 
percentage decrement score (Sdec) (Glaister, Howatson, Pattison, & McInnes, 2008). This 1379 
second method takes into consideration all the sprints, instead of using only the best 1380 
and worst performance (equation 2). It is considered better because it is not dependent 1381 
on only two sprints, but on all of them, and therefore it is more reliable and accurate 1382 
(Glaister et al., 2008). 1383 
𝑆𝑑𝑒𝑐 =  {
(𝑆1+𝑆2+𝑆3+⋯+𝑆𝑓𝑖𝑛𝑎𝑙
𝑆𝑏𝑒𝑠𝑡 𝑥 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑝𝑟𝑖𝑛𝑡𝑠
− 1}  𝑥 100 (Eq. 2) 1384 
It is important to consider that fatigue cannot be the only index taken into consideration 1385 
when analysing RSA performance, as an increase in the best sprinting performance will 1386 
bring a higher fatigue index, but will also increase the mean/peak performance 1387 
parameters. For this reason, other aspects such as the energy metabolism, aerobic and 1388 







2.9.5 Perceptual responses during RSA 1392 
As fatigue is an important factor during RSA, and considering that RPE has been linked 1393 
to fatigue (Guo, Sun, & Zhang, 2017; Madueno, Guy, Dalbo, & Scanlan, 2018), it is 1394 
plausible to expect RPE to increase as fatigue increases in subsequent bouts. 1395 
Furthermore, it has also been shown that RPE increases following an increase of heart 1396 
rate (Coutts, Rampinini, Marcora, Castagna, & Impellizzeri, 2009), further showing that 1397 
RPE is expected to increase between consecutive sprints during a RSA exercise, and 1398 
therefore when the recovery is incomplete. This hypothesis has been confirmed by 1399 
Laurent et al. (2010), Buck et al. (2015) and Halperin et al. (2018), as no differences 1400 
between MC phases have been found in the parameters that can influence RPE. 1401 
Therefore, it might be possible that no differences exist in RPE between the MC phases.  1402 
2.9.6 Effects of hormones on RSA 1403 
Based on the definition of repeated sprint ability, only Middleton & Wenger (2006) 1404 
analysed the effects of the MC phases on RSA performance in female participants. The 1405 
authors reported a higher average work over the series of repeated sprints during the 1406 
late-luteal sub-phase when compared with the mid-follicular, and concluded that higher 1407 
PCr and ATP stores during the luteal phase would help sustain the work levels over the 1408 
last sprints (Gaitanos et al., 1993; Middleton & Wenger, 2006). The higher PCr and ATP 1409 
availability during the luteal phase might also be explained by the higher V̇O2 during the 1410 
recovery between sprints that was found in the luteal phase, allowing the participants 1411 
to replenish more PCr and ATP (Aguiar et al., 2016; Aziz et al., 2000; Jones et al., 2013; 1412 
Sanders et al., 2017). Furthermore, in support to the higher usage of PCr and ATP, a 1413 
lower RER was found during the luteal phase, showing that less glycogen was used, in 1414 
favour of a higher usage of PCr and ATP (Middleton & Wenger, 2006). Due to the higher 1415 
work and recovery V̇O2, and therefore the enhanced ability to maintain a higher 1416 





(Middleton & Wenger, 2006). However, no significant differences were reported 1418 
between the two phases, but no explanation was provided by Middleton & Wenger 1419 
(2006). The author concluded that the difference in work could be translated in 1420 
approximately 1m difference in a 6-seconds sprint, which could be a huge difference in 1421 
a sporting action (reaching the ball, catching your opponent, etc.) (Middleton & Wenger, 1422 
2006). 1423 
To conclude, there is a lack of studies directly measuring the effects of MC on RSA 1424 
performance. To date, only Middleton & Wenger (2006) reported significant 1425 
physiological differences between the MC sub-phases in two variables (V̇O2 and RER). 1426 
Therefore, due to the multi-factorial aspect of RSA performance, and lack of data, it is 1427 
currently not possible to draw clear conclusions about the effects of the MC on RSA 1428 
performance. 1429 
2.10 Hypotheses 1430 
It was hypothesised that the MC sub-phases will affect physiological and perceptual 1431 
parameters, but not the performance measures. Specifically, it is hypothesised that 1432 
heart rate, minute ventilation and RPE will be lower during the mid-follicular sub-phase. 1433 
In contrast, lactate and RER values will be lower during the mid-luteal sub-phase 1434 
compared to the mid-follicular sub-phase, with no changes in V̇O2, power output, 1435 










3. Methods 1442 
3.1 Participants 1443 
Eight physically active females initially agreed to take part in this study, however, only 1444 
six participants were included in the analysis. Two participants were excluded as they 1445 
started to use hormonal and contraceptive medications, respectively during testing. Out 1446 
of the six participants included in the analysis, only four of them completed all the testing 1447 
sessions. One participant missed the second testing session during the mid-luteal sub-1448 
phase due to personal problems and could not come again before the mid-luteal sub-1449 
phase ended (i.e., 86% compliance with the study). Another participant missed both 1450 
sessions during the early-follicular sub-phase because she started using hormonal 1451 
contraceptives due to medical issues (i.e., 71% compliance with the study). However, the 1452 
medical issues did not interfere with the results as they did not affect her hormones 1453 
concentrations and production before starting to use the contraceptive, and therefore 1454 
the participant was included in the study. These two participants were still included in 1455 
the study because their data could be analysed with the correct statistical approach in 1456 
case of missing data. The sample size was determined to be 20 by a power calculation 1457 
(G*Power 3.1), but the number was not reached due to difficulties in recruiting (e.g. 1458 
strict inclusion criteria, participants drop out) and due to the limited time available to 1459 
complete the project.  1460 
From the population assessed four participants were team sport players (one 1461 
badminton, one ice hockey, one football and one rugby union), whilst the fifth 1462 
participant performed ballet and yoga, and the sixth participant did resistance training 1463 
and running. Participants’ baseline parameters and anthropometric measures are 1464 
presented in Table 7. The participation in this study was subject to specific inclusion 1465 
criteria. All participants were training at least three times per week for a full year (any 1466 





least four months, they had to have regular (24 to 35 days) eumenorrheic MCs for no 1468 
less than one year, and menstruating for at least three years at the time of the study 1469 
(Giacomoni et al., 2000; Middleton & Wenger, 2006; Tsampoukos et al., 2010). 1470 
Participants had to be healthy, non-smokers, and not currently under medication or 1471 
treatments that could influence hormones or performance (Stefanovsky et al., 2016). 1472 
The participants were asked to abstain from caffeine, alcohol, and heavy exercises 1473 
during the 24h before each of the sessions, and were instructed to keep their normal 1474 
dietary habits (Casazza, Suh, Miller, Navazio, & Brooks, 2002). Participants were also 1475 
instructed to drink 500ml of water 1h prior to each session, to ensure hydration (Meckel, 1476 
Gottlieb, & Eliakim, 2009). 1477 
Participants were recruited using posters placed around Edinburgh Napier University, 1478 
online posts on social media (Facebook, Twitter, and LinkedIn) or other websites (Reddit) 1479 
and directly contacting female teams in Edinburgh. All participants were asked to 1480 
complete the American College of Sports Medicine (ACSM) Exercise Preparticipation 1481 
Health Screening Questionnaire for Exercise Professionals and provide written consent 1482 
to verify eligibility for the study (Riebe et al., 2015). If the ACSM questionnaire 1483 
highlighted any contraindications to exercising, the participant was excluded from the 1484 
study and informed to contact their GP to get clearance to participate, if they wanted 1485 
to. The research and procedures were approved by the University Ethics Committee of 1486 
Edinburgh Napier University and in regulation with the Declaration of Helsinki for 1487 









Table 7: baseline participant characteristics collected at the first visit. 1493 
Parameter     Participants (n=6) 
Age (years)     25.67 ± 2.49 
Height (m)     1.66 ± 0.08 
Body Mass (kg)     69.8 ± 19.3 
BMI (kg·m-2)     25 ± 6 
Waist circumference (cm)     78.12 ± 12.55 
Hips circumference (cm) 
Waist-to-hip ratio 
    101.42 ± 14.28 
0.77 ± 0.02 
Fat mass (%) 
V̇O2peak (ml·kg-1·min-1) 
    26.72 ± 11.25 
46 ± 6.76 
All data are presented as mean ± standard deviation (SD). 1494 
3.2 First visit 1495 
3.2.1 Documentation 1496 
On the arrival to the Sports and Exercise Science laboratory, the participants had to read 1497 
and complete the Low Energy Availability in Females Questionnaire (LEAF-Q) and ACSM 1498 
questionnaires to verify their eligibility in the study. If they were deemed eligible, they 1499 
were then asked to sign the consent form to participant in the project, allowing data 1500 
collection. 1501 
The ACSM questionnaire was used as a pre-participation health screening questionnaire, 1502 
to identify individuals who may be at risk for exercise practice (Riebe et al., 2015). The 1503 
LEAF-Q is a questionnaire that has been used before to identify female athletes at risk 1504 
for the female athlete triad, and can collect MC related information such as the date of 1505 
your last period, the regularity of your period and the average bleeding length (Melin et 1506 
al., 2014). The LEAF-Q was used to determine the eligibility of the participant in the 1507 
study. 1508 
3.2.2 Baseline measures and anthropometric measures 1509 
Once the questionnaires were completed, blood pressure was measured using a Homron 1510 
Professional Blood Pressure Monitor HEM-907-E7 (Omron, Japan). Participants were 1511 





blood pressure being measured after five minutes of seated rest (Raffalt, Hovgaard-1513 
Hansen, & Jensen, 2013). If the blood pressure was lower than 140/90 mmHg (Mancia 1514 
et al., 2013), participants and researcher signed the consent form to engage in physical 1515 
activity. If the reported blood pressure was higher than 140/90 mmHg (Mancia et al., 1516 
2013), participants were excluded from the study and informed to contact their GP. 1517 
A first measurement of blood lactate at rest was done using the Lactate Pro 2 LT-1730 1518 
(Arkray Factory Inc., Kyoto, Japan). Blood was collected by puncturing the fingertip of 1519 
the participants with a lancing device. The first drop of blood was wiped, with the second 1520 
drop being collected using a lactate strip that absorbed 0.3μL of blood. The strip was 1521 
then inserted in the lactate analyser to provide a blood lactate value after 15 seconds. 1522 
Following the blood lactate measurement, the participant’s height was measured to the 1523 
nearest 1 cm using a stadiometer (Harpenden Portable, Holtain Limited, Dyfed, UK), 1524 
whilst body mass was measured to the nearest 0.1 kg using a mechanical column scale 1525 
(SECA 711, Hamburg, Germany). During the collection of anthropometric data, 1526 
participants were asked to dress as light as possible, and to remove their shoes to 1527 
measure their body mass. Furthermore, participants were asked if they needed to void 1528 
their bladder prior to the beginning of the measurements, to ensure replicability, but 1529 
whether they voided their bladder or not was not confirmed.  1530 
Waist and hip circumferences were also measured using a body tape (SECA, Hamburg, 1531 
Germany), and a Bioelectrical Impedance Analysis (BIA) (Quadscan 4000, Bodystat, UK) 1532 
was used to measure body composition. Waist circumference was measured at the 1533 
narrowest point of the waist, whilst the hip measurement was made at the largest part 1534 
of the buttocks, and both the measurements were made keeping the tape horizontal to 1535 
the ground (Wang et al., 2003; WHO, 2008). The measurement points were assessed 1536 





To use the BIA, the participants were required to lie on a bed. Two adhesive electrodes 1538 
were placed upon the right wrist and right ankle, following the manufacturer’s 1539 
instructions. The device requested to insert information about body mass, height, age, 1540 
circumferences, and activity levels, which we collected previously, and after the analysis 1541 
it provided data about body composition such as lean mass, fat mass and hydration. 1542 
After the collection of the participants’ anthropometric measures, participants were 1543 
required to perform a V̇O2peak test, as indicated in Figure 3. 1544 
 1545 
Figure 3: overview of the steps taken during the first visit, leading to the V̇O2peak test. 1546 
3.2.3 Peak oxygen uptake test 1547 
Participants’ V̇O2peak was determined using an incremental test to exhaustion on a 1548 
motorised treadmill (Ergo ELG-55, Woodway, Germany), performed to volitional 1549 
exhaustion. Following a five minute standardised warm-up, running at a constant speed 1550 
of 9.6 km/h at 0% gradient, the speed was increased to 11.2 km/h were the set speed 1551 
remained, and every two minutes the gradient was increased by 2.5% (Figure 4) 1552 










Figure 4: V̇O2peak protocol. On the left, the figure shows the speed in relation to the time. On the right, the figure 1559 
shows the gradient in relation to the time. 1560 
During the test, exchanged air was analysed using a breath-by-breath gas analyser 1561 
(Metalyzer 3B, Cortex, Leipzig, Germany). Expired gases were collected through a mask 1562 
that participants had to wear, that allowed the Cortex to analyse the airflow through the 1563 
mask. The Cortex was prepared following the manufacturer’s instructions, performing 1564 
the calibration approximately 30 minutes before every use. The calibration included 1565 
three steps: the gas calibration of O2 and CO2 analyser, the calibration of the volume 1566 
transducer and the calibration of the pressure analysed. Heart Rate (HR) was monitored 1567 
using an H7 Bluetooth Polar HR monitor (Polar, Kempele, Finland), which was linked with 1568 
the Cortex Metalyzer. 1569 
Immediately after the test, the Rating of Perceived Exertion (RPE) data were collected 1570 
using the 6-20 Borg scale, by verbally asking the participant to give a number between 6 1571 
and 20, where 6 corresponded to the lowest exertion (rest) and 20 being the highest 1572 
exertion possible (Borg, 1982). The first of three post-exercise measures of blood lactate 1573 
were collected immediately after finishing the peak oxygen uptake test. The second 1574 
blood lactate measure was done three minutes after the exercise, and the last one was 1575 
done five minutes after the exercise completion, following the procedures explained 1576 
earlier. 1577 
3.3 Menstrual cycle phases determination 1578 
The procedure to predict and determine the MC phases started immediately after the 1579 





diary (FitrWoman, https://www.fitrwoman.com/, Orreco Limited, Ireland) and a urinary 1581 
kit (Clearblue Advanced Digital Ovulation Test, SPD Swiss Precision Diagnostics, Geneva, 1582 
Switzerland) was chosen for this project, in order to increase the chances to detect 1583 
ovulation (Mattu et al., 2019; Wideman et al., 2013). The participants started to use the 1584 
electronic diary immediately after the first visit, and the urinary kit after the first 1585 
menstruation following the third visit, as shown in Figure 5. Participants had to 1586 
communicate with the researcher through an online survey (Novi Survey, USA) the first 1587 
day of bleeding, the last day of bleeding, and the results from the urinary kit to detect 1588 
ovulation. The data from the survey allowed for the determination of the MC phases, 1589 
with the determination of the early-follicular sub-phase being two days from the 1590 
beginning of bleeding until the seventh day (Janse de Jonge, 2003). Once ovulation was 1591 
indicated, the mid-luteal sub-phase was classified as four days post ovulation to ten days 1592 
post (Janse de Jonge, 2003; Köse, 2018; Pestana et al., 2017; Stefanovsky et al., 2016). 1593 
The ovulation was considered to have occurred 24h after the LH surge was detected. 1594 
 1595 
Figure 5: visual representation of the phases of the project. Each number corresponds to a session (1: first visit, 2-3: 1596 
familiarisation sessions, 4-5: early-follicular sessions, 6-7: mid-luteal sessions). The letter A is the time spent waiting 1597 
from the second familiarisation to the beginning of the first new MC. The letter B is the time used to gather the last 1598 
MC data with the smartphone application. Below the main line, it is indicated when the urinary kit was used and when 1599 
the smartphone app was used (from the beginning to the end of the project). 1600 
The main purpose of FitrWoman app was to collect data about the length of the MC, to 1601 





cycle. This application was previously reviewed by Brown (2018) and was found to be 1603 
interactive and easy to use. 1604 
To determine the LH surge, the Clearblue Advanced Digital Ovulation Test was used. This 1605 
test determines when to indicate high fertility by looking for a marked increase in 1606 
oestrogen concentration (Clearblue Technical Support, personal communication, 1st 1607 
August 2019). In order to measure an increase, the test initially establishes a baseline 1608 
concentration of the hormone before it becomes elevated at the start of the fertile 1609 
period (Clearblue Technical Support, personal communication, 1st August 2019). The 1610 
baseline concentration is set with the first test of a new cycle of use and then adjusted 1611 
with every subsequent test until high fertility is detected and indicated (Clearblue 1612 
Technical Support, personal communication, 1st August 2019). The holder will then 1613 
continue to display High Fertility after each test until it detects the LH surge to 40 mIU/ml 1614 
and will then display Peak Fertility (Clearblue Technical Support, personal 1615 
communication, 1st August 2019). The holder can detect an LH surge as low as 22 mIU/ml 1616 
depending on the hormone concentrations of previous results as it can adjust its 1617 
sensitivity (Clearblue Technical Support, personal communication, 1st August 2019). 1618 
Following the manufacturer instructions, the test was done once per day after sleeping, 1619 
using the first urine of the day. Based on the MC length information that was collected 1620 
using a questionnaire and referring to a table provided by the manufacturer (Table 8), 1621 
the starting day of the test was decided. 1622 
Table 8: starting day for the utilisation of the urinary kit 1623 
Your cycle 
length in days 
≤21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 ≥41 
Start testing on 
the day next to 
your cycle 
length 










To take the test the participants had to place the absorbent tip pointing downwards to 1625 
the urine stream for two seconds. Alternatively, the participant was able to collect a 1626 
sample of urine in a clean and dry container and dip the absorbent tip in the urine for 15 1627 
seconds. At this point, after waiting for five minutes, the results would appear on the 1628 
screen, showing one of the three possible results (Figure 6). If a circle was shown, it 1629 
indicated low fertility. If a flashing smiley face was shown, the test detected a rise in 1630 
oestrogen concentrations. In this case, the participant had to continue to test daily to 1631 
find the LH surge. In this phase, testing more than once per day was allowed. If a static 1632 
smiley face was shown, the test detected the LH surge. 1633 
 1634 
Figure 6: visual results from the Clearblue Advanced Digital Ovulation Test. 1635 
3.4 Repeated Sprint Ability intervention (4th - 7th visits) 1636 
After the first visit, all the participants were required to complete two familiarisation 1637 
trials before doing the four intervention sessions. All the sessions were successfully 1638 
completed by every participant, and were conducted in the Sport and Exercise Science 1639 
laboratory in a controlled environment (temperature: 20.92 ± 0.97 °C, humidity: 32.79 ± 1640 
9.54 %). During the familiarisation and intervention sessions, participants performed the 1641 
same protocol with at least 24h of rest between consecutive sessions. Physiological, 1642 
perceptual and performance data were collected to check repeatability of measures, to 1643 








3.4.1 Baseline measures and anthropometric measures 1648 
At the arrival at the laboratory, the participants were asked to lie down, and the blood 1649 
pressure was measured, followed by a blood lactate measurement at rest. After this, 1650 
anthropometric measures were collected (body mass, height, circumferences, BIA) 1651 
following the procedures explained in section 3.2.1. 1652 
3.4.2 RSA protocol 1653 
After these measurements, the participants performed a standardised warm up of five 1654 
minutes running at a self-selected speed on a non-motorised Force treadmill (Force 3.0, 1655 
Woodway, Germany), before performing the RSA intervention. The RSA protocol 1656 
consisted of five ‘all-out’ sprints of six seconds from a standing start on the non-1657 
motorised treadmill with 24 seconds of active recovery (walking) between the sprints 1658 
(McGawley & Bishop, 2006). The participants were verbally encouraged throughout the 1659 
exercise, and they were given verbal instructions by the researcher about what to do in 1660 
each phase.  1661 
During the test, a breath-by-breath gas analyser (Metalyzer 3B, Cortex, Leipzig, 1662 
Germany) was used to measure exchanged air continuously, and the heart rate was 1663 
continuously monitored using an H7 Bluetooth Polar HR monitor (Polar, Kempele, 1664 
Finland), following the same procedures utilised during the peak oxygen uptake test, and 1665 
using the same instruments. For every parameter, the mean value during each sprint 1666 
without including rest periods was used for analysis. Moreover, during the recovery time 1667 
between the sprints the Rating of Perceived Exertion (RPE) data were collected using the 1668 
6-20 Borg scale, by asking the participant to verbally give a number between six and 20 1669 
(Borg, 1982). 1670 
The peak values of the physiological parameters during each sprint were not analysed 1671 





each breath and the breaths were not synchronised with the sprinting times, the data 1673 
collected could not be perfectly synchronised with the sprints. For this reason, the data 1674 
in each sprint have been manually selected trying to be as accurate as possible (i.e. 1675 
selecting only the data collected during the sprint, as close as possible). However, as the 1676 
peak values were found to be at the end of the sprint and therefore near to where we 1677 
selected the data manually, a manual mistake could have affected the results. Averaging 1678 
the data during the selected interval, instead, allowed us to avoid this problem. 1679 
Performance data were collected by the treadmill that provided power, acceleration and 1680 
distance every 0.005 seconds. Mean values for power output during each sprint, peak 1681 
values for power output and acceleration during each sprint, and distance were used for 1682 
analysis. The fatigue index was calculated for mean and peak power output and peak 1683 
acceleration, using the formula presented in section 2.9.4 (Sdec). 1684 
After the intervention, three additional measures of blood lactate were done following 1685 
the same procedures and using the same materials explained previously. The first 1686 
measure was done immediately after the exercise, the second one after three minutes 1687 
and the last one after five minutes after the exercise completion (Figure 7).  1688 
 1689 
Figure 7: RSA protocol, starting from the first measure of pre-exercise lactate. 1: pre-exercise lactate measurement; 1690 
2: rest between the warm-up and the RSA protocol; 3: post-exercise lactate measurement; A: 24 seconds walking; B: 1691 






3.5 Statistical analysis 1694 
Normal distribution was assessed using the Shapiro-Wilk test. To analyse the differences 1695 
between the familiarisation, the early-follicular and the mid-luteal sub-phases, a mixed-1696 
effects model (restricted maximum likelihood (REML)) was used for performance 1697 
parameters (distance, peak acceleration, mean power output, peak power output), 1698 
physiological parameters (post-exercise lactate, heart rate, V̇O2, RER, Ve) and perceptual 1699 
parameters (RPE). A one-way ANOVA was used to analyse body composition parameters 1700 
(BMI, fat mass, hips-to-waist ratio), fatigue indexes and pre-exercise lactate because 1701 
these parameters were collected only once, and not after every sprint. A Geisser-1702 
Greenhouse correction for violation of sphericity was used. Non-normally distributed 1703 
data (fatigue index for mean power output) were analysed with a Friedman test. If 1704 
significance was found between the familiarisation, the early-follicular and the mid-1705 
luteal sub-phase, a Tukey’s multiple comparison test was used to further analyse the 1706 
data and see which phases were significantly different.  1707 
To analyse the differences between two sessions of the same phase, a two-way ANOVA 1708 
with repeated measures, or a mixed-effects model (REML) in case of missing data, were 1709 
used for performance parameters (distance, peak acceleration, mean power output, 1710 
peak power output), physiological parameters (post-exercise lactate, heart rate, V̇O2, 1711 
RER, Ve) and perceptual parameters (RPE). A Geisser-Greenhouse correction for 1712 
violation of sphericity was used. A Student’s paired t-test was used to analyse the 1713 
differences in body composition parameters (BMI, fat mass, hips-to-waist ratio), fatigue 1714 
indexes and pre-exercise lactate between two sessions of the same phase. Non-normally 1715 
distributed data (V̇O2, mean power output, HR, V̇e, fatigue index for mean power output) 1716 
were analysed with a Wilcoxon matched-pairs signed-rank test. 1717 
All statistical analyses were carried out using GraphPad Prism (version 8.4.0) for 1718 





statistical significance being set at p ≤ 0.05. Effect sizes were reported using Cohen’s d, 1720 
described as trivial (0.00 – 0.19), small (0.20 – 0.59), moderate (0.60 – 1.19), large (1.20 1721 
– 1.99), and very large (2.0 – 4.0) (Hopkins, Marshall, Batterham, & Hanin, 2009). 1722 
Furthermore, the difference between means was reported as a measure of effect size 1723 
when a comparison between two groups was done. All data were reported as group 1724 




















4. Results 1741 
4.1 Participant’s characteristics 1742 
Participants’ BMI did not significantly differ between the familiarisation (23 ± 5 kg·m-2), 1743 
EF (23 ± 5 kg·m-2) and ML (24 ± 5 kg·m-2) (p = 0.29) (Table 9). Furthermore, no significant 1744 
differences were found between EF and ML (p = 0.35, d = 0.2, difference between means 1745 
= -0.4 kg·m-2 (1.71 %)) (Table 9). No significant differences were also found when 1746 
comparing BMI measures between the two sessions of F (25 ± 6 kg·m-2 vs 25 ± 6 kg·m-2) 1747 
(p = 0.18, d = 0.65, difference between means = 0.3 kg·m-2 (-1.19 %)), EF (23 ± 5 kg·m-2 1748 
vs 24 ± 5 kg·m-2) (p = 0.37, d = 0.45, difference between means = -0.2 kg·m-2 (0.85 %)) or 1749 
ML (26 ± 6 kg·m-2 vs 26 ± 6 kg·m-2) (p = 0.18, d = 0.73, difference between means = 0.4 1750 
kg·m-2 (-1.53 %)). 1751 
No significant differences were found in fat mass between the familiarisation (23.71 ± 1752 
10.74 %), EF (24.47 ± 8.94 %) and ML (23.93 ± 10.53 %) (p = 0.92) (Table 9). A comparison 1753 
between EF and ML showed non-significant differences (p = 0.93, d = 0.23, difference 1754 
between means = 0.54 % (-2.21 %)) (Table 9). Moreover, fat mass did not significantly 1755 
differ between the two sessions of the familiarisation (27.43 ± 15.52 % vs 27.50 ± 15.72 1756 
%) (p = 0.94, d = 0.00 difference between means = -0.07 % (0.26 %)), EF (24.98 ± 8.94 % 1757 
vs 23.96 ± 9.07 %) (p = 0.36, d = 0.11, difference between means = 1.02 % (-4.08 %)), or 1758 
ML (28.63 ± 14.41 % vs 28.20 ± 13.59 %) (p = 0.76, d = 0.03, difference between means 1759 
= 0.43 % (-1.50 %)). 1760 
Hips-to-waist ratio among participants did not significantly differ between the 1761 
familiarisation (0.76 ± 0.03), EF (0.76 ± 0.03) and ML (0.77 ± 0.03) (p = 0.98) (Table 9). 1762 
There were no significant differences between EF and ML (p = 0.98, d = 0.33, difference 1763 
between means = -0.01 (1.32 %)) (Table 9). No significant differences were found in hips-1764 





(p = 0.80, d = 0.00), EF (0.76 ± 0.03 vs 0.76 ± 0.03) (p > 0.99, d = 0.11), or ML (0.76 ± 0.03 1766 
vs 0.77 ± 0.03) (p = 0.48, d = 0.33, difference between means = -0.01 (1.32 %)). 1767 
Table 9: comparison of body composition parameter during the familiarisation, early-follicular and mid-luteal sub-1768 
phases. 1769 
Parameter Familiarisation Early-follicular Mid-luteal 
BMI 23 ± 5 23 ± 5 24 ± 5 
Fat mass (%) 23.71 ± 10.74 24.47 ± 8.94 23.93 ± 10.53 
Hips-to-waist ratio 0.76 ± 0.03 0.76 ± 0.03 0.77 ± 0.03 
 1770 
4.2 HR 1771 
HR was not significantly different between the familiarisation (159.04 ± 21.52 bpm), EF 1772 
(159.08 ± 20.36 bpm) and ML (155.55 ± 20.43 bpm) (p = 0.40) (Figure 8). No significant 1773 
differences were found between EF and ML (p = 0.49, d = 0.17, difference between 1774 
means = 3.23 bpm (-2.22 %)) (Figure 8). Furthermore, HR was not found to differ 1775 
significantly between the two sessions of the familiarisation (158.66 ± 22.05 bpm vs 1776 
156.93 ± 18.47 bpm) (p = 0.81, d = 0.09, difference between means = 1.73 bpm (-1.09 1777 
%)), EF (158.25 ± 20.13 bpm vs 159.92 ± 20.93 bpm) (p = 0.13, d = 0.08, difference 1778 
between means = -1.67 bpm (1.06 %)) and ML (156.28 ± 19.56 bpm vs 162.28 ± 19.36 1779 













Figure 8: comparison of HR during the familiarisation (F), early-follicular (EF) and mid-luteal (ML) sub-phases of the 1789 
MC (Mean ± SD). ○: participant 1; □: participant 2; ▲: participant 3; ◇: participant 4; ⬣: participant 5; ✖: participant 1790 
6. 1791 
4.3 Lactate 1792 
The differences in pre-exercise baseline lactate levels were not found to be significant 1793 
between the familiarisation (1.30 ± 0.50 mmol·l-1), EF (1.43 ± 0.46 mmol·l-1) and ML (1.63 1794 
± 0.51 mmol·l-1) (p = 0.51). Moreover, pre-exercise lactate levels did not differ between 1795 
EF and ML (p = 0.78, d = 0.41, difference between means = -0.20 mmol·l-1 (13.99 %)) 1796 
(Figure 9). No significant differences were found in pre-exercise lactate between the two 1797 
sessions of the familiarisation (1.26 ± 0.30 mmol·l-1 vs 1.38 ± 0.81 mmol·l-1) (p = 0.59, d 1798 
= 0.20, difference between means = -0.12 mmol·l-1 (9.52 %)), EF (1.20 ± 0.56 mmol·l-1 vs 1799 
1.62 ± 0.44 mmol·l-1) (p = 0.17, d = 0.83, difference between means = -0.42 mmol·l-1 1800 
(35%)), or ML (1.60 ± 0.52 mmol·l-1 vs 1.58 ± 0.53 mmol·l-1) (p = 0.46, d = 0.04, difference 1801 
between means = 0.02 mmol·l-1 (-1.25 %)). 1802 
Post-exercise lactate levels were non-significant between the familiarisation (12.19 ± 1803 
2.80 mmol·l-1), EF (12.66 ± 3.11 mmol·l-1) and ML (12.01 ± 2.32 mmol·l-1) (p = 0.31) (Figure 1804 
9). Furthermore, post-exercise lactate did not significantly between EF and ML (p = 0.58, 1805 





in post-exercise lactate were also not significant between the two sessions of the 1807 
familiarisation (12.34 ± 3.55 mmol·l-1 vs 12.04 ± 2.61 mmol·l-1) (p = 0.67, d = 0.09, 1808 
difference between means = 0.3 mmol·l-1 (-2.43 %)), EF (12.32 ± 3.34 mmol·l-1 vs 12.85 ± 1809 
3.08 mmol·l-1) (p = 0.17, d = 0.17, difference between means = -0.53 mmol·l-1 (4.30 %)), 1810 
or ML (12.14 ± 2.56 mmol·l-1 vs 11.78 ± 2.45 mmol·l-1) (p = 0.46, d = 0.14, difference 1811 
between means = 0.36 mmol·l-1 (-2.97 %)). 1812 
 1813 
Figure 9: comparison of pre-exercise lactate (left) and post-exercise lactate (right) during the familiarisation (F), early-1814 
follicular (EF) and mid-luteal (ML) sub-phases of the MC (Mean ± SD). ○: participant 1; □: participant 2; ▲: participant 1815 
3; ◇: participant 4; ⬣: participant 5; ✖: participant 6. 1816 
4.4 V̇O2 1817 
No significant differences were found in V̇O2 between the familiarisation (34.10 ± 9.50 1818 
ml·kg-1·min-1), EF (35.65 ± 8.68 ml·kg-1·min-1) and ML (32.97 ± 8.97 ml·kg1·min-1) (p = 0.33) 1819 
(Figure 10). A comparison between EF and ML showed non-significant differences (p = 1820 
0.10, d = 0.30, difference between means = 2.68 ml·kg-1·min-1 (-7.52 %)) (Figure 10). 1821 
Furthermore, V̇O2 was not found to differ between the two sessions of the 1822 
familiarisation (32.13 ± 8.92 ml·kg-1·min-1 vs 33.07 ± 11.05 ml·kg-1·min-1) (p = 0.06, d = 1823 
0.09, difference between means = -0.94 ml·kg-1·min-1 (2.93 %)), EF (36.33 ± 8.29 ml·kg-1824 





1.36 ml·kg-1·min-1 (-3.74 %)) and ML (33.00 ± 8.81 ml·kg-1·min-1 vs 31.39 ± 8.80 ml·kg-1826 
1·min-1) (p = 0.06, d = 0.18, difference between means = 1.61 ml·kg-1·min-1 (-4.88 %)). 1827 
 1828 
Figure 10: comparison of V̇O2 during the familiarisation (F), early-follicular (EF) and mid-luteal (ML) sub-phases of the 1829 
MC (Mean ± SD). ○: participant 1; □: participant 2; ▲: participant 3; ◇: participant 4; ⬣: participant 5; ✖: participant 1830 
6. 1831 
4.5 RER 1832 
RER was not significantly different between the familiarisation (1.09 ± 0.16), EF (1.11 ± 1833 
0.15) and ML (1.09 ± 0.16) (p = 0.75) (Figure 11). A comparison between EF and ML 1834 
showed non-significant differences (p = 0.47, d = 0.13, difference between means = 0.02 1835 
(- 1.80%)) (Figure 11). No significant differences were found in RER between the two 1836 
sessions of the familiarisation (1.06 ± 0.19 vs 1.12 ± 0.18) (p = 0.13, d = 0.32, difference 1837 
between means = -0.06 (5.66 %)), EF (1.11 ± 0.18 vs 1.10 ± 0.14) (p = 0.61, d = 0.06, 1838 
difference between means = 0.01 (-0.9 %)) and ML (1.07 ± 0.16 vs 1.10 ± 0.17) (p = 0.21, 1839 









Figure 11: comparison of RER during the familiarisation (F), early-follicular (EF) and mid-luteal (ML) sub-phases of the 1845 
MC (Mean ± SD). ○: participant 1; □: participant 2; ▲: participant 3; ◇: participant 4; ⬣: participant 5; ✖: participant 1846 
6. 1847 
4.6 V̇e 1848 
The differences in V̇e were not found to be significant between the familiarisation (84.97 1849 
± 21.41 l·min-1), EF (91.73 ± 19.82 l·min-1) and ML (89.10 ± 25.36 l·min-1) (p = 0.08) (Figure 1850 
12). Moreover, V̇e did not significantly differ between EF and ML (p = 0.42, d = 0.12, 1851 
difference between means = 2.63 l·min-1 (-2.87 %)) (Figure 12). V̇e was not found to 1852 
significantly differ between the two session of the familiarisation (85.49 ± 22.00 l·min-1 1853 
vs 84.45 ± 24.25 l·min-1) (p = 0.63, d = 0.04, difference between means = 1.04 l·min-1 (-1854 
1.22 %)), EF (94.14 ± 21.09 l·min-1 vs 89.32 ± 19.54 l·min-1) (p = 0.13, d = 0.24, difference 1855 
between means = 4.82 l·min-1 (-5.12 %)) and ML (86.90 ± 25.43 l·min-1 vs 89.39 ± 27.60 1856 










Figure 12: comparison of V̇e during the familiarisation (F), early-follicular (EF) and mid-luteal (ML) sub-phases of the 1863 
MC (Mean ± SD). ○: participant 1; □: participant 2; ▲: participant 3; ◇: participant 4; ⬣: participant 5; ✖: participant 1864 
6. 1865 
4.7 RPE 1866 
Significant differences were found in RPE between the familiarisation (13.82 ± 1.91), EF 1867 
(13.42 ± 2.15) and ML (12.60 ± 2.26) (p = 0.001) (Figure 13). The adjusted P value after a 1868 
Tukey’s multiple comparison test showed a significant difference between EF and ML (p 1869 
< 0.001, d = 0.37, difference between means = 0.82 (-6.11 %)), and between the 1870 
familiarisation and ML (p < 0.001, d = 0.58, difference between means = 1.22 (-8.83%)) 1871 
(Figure 13). Comparison within sub-phases also showed significant differences between 1872 
the two sessions of the familiarisation (14.21 ± 1.97 vs 13.37 ± 1.96) (p < 0.001, d = 0.43, 1873 
difference between means = 0.74 (-5.91 %)). However, no significant differences were 1874 
found within the two sessions of EF (13.48 ± 1.98 vs 13.36 ± 2.43) (p = 0.59, d = 0.05, 1875 
difference between means = 0.12 (-0.89 %)) or ML (12.57 ± 2.33 vs 12.58 ± 2.47) (p = 1876 






Figure 13: comparison of RPE during the familiarisation (F), early-follicular (EF) and mid-luteal (ML) sub-phases of the 1879 
MC (Mean ± SD). ○: participant 1; □: participant 2; ▲: participant 3; ◇: participant 4; ⬣: participant 5; ✖: participant 1880 
6. ****: p < 0.0001. 1881 
4.8 Power output 1882 
MPO was not found to significantly differ between the familiarisation (1375.15 ± 205.19 1883 
W), EF (1406.33 W ± 208.97 W) and ML (1405.71 ± 212.86 W) (p = 0.17) (Figure 14). Non-1884 
significant differences were also found between EF and ML (p = 0.998, d = 0.00, 1885 
difference between means = 0.62 W (-0.4 %)) (Figure 14). No significant differences were 1886 
found in MPO between the two sessions of the familiarisation (1379.77 ± 218.14 W vs 1887 
1370.54 ± 204.24 W) (p = 0.63, d = 0.04, difference between means = 9.23 W (-0.67 %)), 1888 
EF (1413.23 ± 197.44 W vs 1399.44 ± 226.32 W) (p = 0.31, d = 0.06, difference between 1889 
means = 13.79 W (-0.98 %)) or ML (1400.95 ± 211.09 W vs 1407.39 ± 237.50 W) (p = 0.44, 1890 
d = 0.03, difference between means = -6.44 W (0.46 %)). The fatigue index for MPO did 1891 
not significantly differ between the familiarisation (-6.64 ± 2.28), EF (-7.59 ± 1.72) and 1892 
ML (-5.69 ± 1.48) (p = 0.37). Non-significant differences were found between EF and ML 1893 
(p = 0.25, d = 1.18, difference between means = -1.9 (-25.03 %)). Furthermore, no 1894 





familiarisation sessions (-7.86 ± 3.34 vs -5.44 ± 2.66) (p = 0.16, d = 0.80, difference 1896 
between means = -2.42 (-30.79 %)), EF (-7.56 ± 1.29 vs -7.63 ± 2.74) (p = 0.81, d = 0.03, 1897 
difference between means = 0.07 (0.93 %)), or ML (-5.24 ± 3.05 vs -5.79 ± 0.43) (p > 0.99, 1898 
d = 0.25, difference between means = 0.55 (10.50 %)). 1899 
 1900 
Figure 14: comparison of MPO during the familiarisation (F), early-follicular (EF) and mid-luteal (ML) sub-phases of the 1901 
MC (Mean ± SD). ○: participant 1; □: participant 2; ▲: participant 3; ◇: participant 4; ⬣: participant 5; ✖: participant 1902 
6. 1903 
Similar to MPO, no significant differences were found in PPO between the familiarisation 1904 
(2431.06 ± 402.78 W), EF (2498.32 ± 383.56 W) and ML (2432.75 ± 417.10 W) (p = 0.97) 1905 
(Figure 15). A comparison between EF and ML indicated non-significant differences (p = 1906 
0.14, d = 0.16, difference between means = 65.57 W (0.07 %)) (Figure 15). No significant 1907 
differences were found in PPO between the session of the familiarisation (2455.38 ± 1908 
421.65 W vs 2406.73 ± 403.85 W) (p = 0.17, d = 0.12, difference between means = 48.65 1909 
W (-1.98 %)), EF (2509.60 ± 425.65 W vs 2487.04 ± 357.41 W) (p = 0.52, d = 0.06, 1910 
difference between means = 22.56 W (-0.90 %)) or ML (2442.19 ± 441.90 W vs 2409.43 1911 
± 445.11 W) (p = 0.55, d = 0.07, difference between means = 32.76 W (-1.34 %)). The 1912 
fatigue index for PPO was not found to significantly differ between the familiarisation (-1913 





and ML showed non-significant differences (p = 0.30, d = 1.26, difference between 1915 
means = -2.08 (-30.10 %)). However, significant differences were found in the fatigue 1916 
index for PPO between the two familiarisation sessions (-5.86 ± 3.28 vs -8.11 ± 3.05) (p 1917 
= 0.03, d = 0.71, difference between means = 2.25 (38.40 %)). Yet, no significant 1918 
differences were found between the two sessions of EF (-7.04 ± 3.95 vs -6.78 ± 3.97) (p 1919 
= 0.93, d = 0.07, difference between means = -0.26 (-3.69 %)), or ML (-5.15 ± 1.27 vs -1920 
5.06 ± 1.44) (p = 0.93, d = 0.07, difference between means = -0.09 (-1.75 %)). 1921 
 1922 
Figure 15: comparison of PPO during the familiarisation (F), early-follicular (EF) and mid-luteal (ML) sub-phases of the 1923 
MC (Mean ± SD). ○: participant 1; □: participant 2; ▲: participant 3; ◇: participant 4; ⬣: participant 5; ✖: participant 1924 
6. 1925 
4.9 Peak acceleration 1926 
Significant differences were found in peak acceleration between the familiarisation (4.66 1927 
± 0.77 m·s-2), EF (4.65 ± 0.84 m·s-2) and ML (5.05 ± 1.14 m·s-2) (p = 0.03) (Figure 16). The 1928 
adjusted P value after a Tukey’s multiple comparison test showed significant differences 1929 
between EF and ML (p = 0.02, d = 0.40, difference between means = -0.4 m·s-2 (8.60%)), 1930 
and between the familiarisation and ML (p = 0.04, d = 0.40, difference between means 1931 
= -0.39 m·s-2 (8.37 %)) (Figure 16). However, no significant differences were found in the 1932 





0.85 m·s-2 vs 4.79 ± 0.87 m·s-2) (p = 0.08, d = 0.29, difference between means = -0.25 m·s-1934 
2 (5.51%)), EF (4.67 ± 0.87 m·s-2 vs 4.65 ± 0.95 m·s-2) (p = 0.88, d = 0.02, difference 1935 
between means = 0.02 m·s-2 (-0.43%)) or ML (5.02 ± 1.11 m·s-2 vs 4.96 ± 1.32 m·s-2) (p = 1936 
0.71, d = 0.05, difference between means = 0.06 m·s-2 (-1.20%)). Significant differences 1937 
were also found in the fatigue index for acceleration (Sdec) between the familiarisation 1938 
(-16.07 ± 3.45), EF (-12.39 ± 3.44) and ML (-9.91 ± 3.89) (p = 0.03). Specifically, there was 1939 
a significant difference between the familiarisation and ML (p = 0.03, d = 1.68, difference 1940 
between means = -6.16 (-38.33 %)). Non-significant differences were found between EF 1941 
and ML (p = 0.51, d = 0.68, difference between means = -2.48 (-20.02 %)). The fatigue 1942 
index for acceleration did not significantly differ between the two sessions of the 1943 
familiarisation (-16.46 ± 4.45 vs -15.69 ± 4.14) (p = 0.69, d = 0.18, difference between 1944 
means = -0.77 (-4.68 %)), EF (-10.89 ± 4.90 vs -13.88 ± 2.97) (p = 0.20, d = 0.74, difference 1945 
between means = 2.99 (27.46%)), or ML (-9.04 ± 3.63 vs -11.46 ± 7.13) (p = 0.51, d = 0.43, 1946 
difference between means = 2.42 (26.77%)). 1947 
 1948 
Figure 16: comparison of peak acceleration during the familiarisation (F), early-follicular (EF) and mid-luteal (ML) sub-1949 
phases of the MC (Mean ± SD). ○: participant 1; □: participant 2; ▲: participant 3; ◇: participant 4; ⬣: participant 5; 1950 






4.10 Distance 1953 
Distance was not found to be significantly different between the familiarisation (20.14 ± 1954 
2.56 m), EF (20.47 ± 2.44 m) and ML (20.31 ± 2.47 m) (p = 0.49) (Figure 17). Moreover, a 1955 
multiple comparison specifically showed non-significant differences between EF and ML 1956 
(p = 0.59, d = 0.07, difference between means = 0.16 m (-0.78 %)) (Figure 17). No 1957 
significant differences were also found in distance between the two sessions of the 1958 
familiarisation (20.27 ± 2.78 m vs 20.01 ± 2.54 m) (p = 0.35, d = 0.10, difference between 1959 
means = -0.26 m (-1.28 %)), EF (20.57 ± 2.36 m vs 20.37 ± 2.63 m) (p = 0.38, d = 0.08, 1960 
difference between means = 0.20 m (-0.97 %)) or ML (20.29 ± 2.45 m vs 20.25 ± 2.76 m) 1961 
(p = 0.82, d = 0.02, difference between means = 0.04 m (-0.20 %)). 1962 
 1963 
Figure 17: comparison of mean distance across all five sprints during the familiarisation (F), early-follicular (EF) and 1964 
mid-luteal (ML) sub-phases of the MC (Mean ± SD). ○: participant 1; □: participant 2; ▲: participant 3; ◇: participant 1965 










5. Discussion 1972 
The aim of this study was to measure physiological, performance and perceptual 1973 
responses during repeated running sprint ability induced by the early-follicular and mid-1974 
luteal sub-phases of the MC. It was hypothesised that the MC phases would affect 1975 
physiological and perceptual parameters, but not the performance (peak power output, 1976 
mean power output, distance, peak acceleration). Data suggest that the MC phases 1977 
might not influence anthropometric parameters (BMI (p = 0.35)), hips-to-waist ratio (p = 1978 
0.98), fat mass (p = 0.93)), physiological parameters (V̇O2 (p = 0.10), HR (p = 0.49), Ve (p 1979 
= 0.42), RER (p = 0.47), pre- (p = 0.78) and post-exercise lactate (p = 0.58)) and 1980 
performance parameters (mean power (p = 0.998), peak power (p = 0.14 ), distance (p = 1981 
0.59)). No significant differences between EF and ML in any of the above-mentioned 1982 
parameters are the major findings of the current study. However, results from the 1983 
present study also found that the MC phases appear to influence RPE and peak 1984 
acceleration. RPE was found to be significantly lower during ML when compared with EF 1985 
(p < 0.001). Whereas, peak acceleration was found to be significantly higher during ML 1986 
when compared with EF (p = 0.02). Furthermore, trivial or small effect sizes were 1987 
identified for all the variables analysed between EF and ML, except for the fatigue 1988 
indexes, showing that the magnitude of the effects of the MC on fatigue indexes is bigger 1989 
than the other parameters analysed. 1990 
5.1 Participant’s characteristics 1991 
The results from this study show non-significant difference in any of the body 1992 
composition parameters analysed (BMI, fat mass, hips-to-waist circumference). Janse de 1993 
Jonge (2003) and Giacomoni et al. (2000) suggested that body composition could be 1994 
affected by the MC through fluid regulation. However, Janse de Jonge (2003) and 1995 
Giacomoni et al. (2000) also reported that the MC effect on fluid regulation might not 1996 





effect sizes reported in BMI (d = 0.2), fat mass (d = 0.23) and hips-to-waist circumference 1998 
(d = 0.33) in the present study (Table 9). The findings agree with previous studies that 1999 
did not find any differences in body composition between EF and ML (Beidleman et al., 2000 
1999; Bemben et al., 1995; De Souza et al., 1990; Julian et al., 2017; Lebrun et al., 1995). 2001 
However, whilst specific instructions were given about fluid intake prior to testing, it was 2002 
not directly controlled in this study and in any of the studies reviewed, and therefore 2003 
further studies should be done to assess the influence of the MC on fluid regulation and 2004 
its effects on body composition.  2005 
Fat mass was not found to differ between EF and ML (EF: 24.47 ± 8.94 %, ML: 23.93 ± 2006 
10.53  %, p = 0.93), as also confirmed by previous studies from Lebrun et al. (1995), De 2007 
Souza et al. (1990) and Julian et al. (2017). Hips-to-waist circumference differences 2008 
between EF and ML were also found non-significant (EF: 0.76 ± 0.03, ML: 0.77 ± 0.03, p 2009 
= 0.98). However, as the effects of the MC on hips-to-waist circumference were never 2010 
analysed previously, it is not possible to compare the results from this study with 2011 
previous literature. The BMI differences between EF and ML were also found to be non-2012 
significant (EF: 23 ± 5 kg·m-2, ML: 24 ± 5 kg·m-2, p = 0.35). BMI has been previously 2013 
analysed, but the differences between sub-phases were not reported, and therefore a 2014 
comparison between the results of this study and previous literature is not possible. 2015 
However, in agreement with our results, Vaiksaar et al. (2011) reported non-significant 2016 
differences in BMI between the luteal and follicular phases, and Pestana et al. (2017) 2017 
reported non-significant differences in BMI between MF and the late-luteal sub-phase. 2018 
Even though the number of the studies reporting BMI is low, the results agree with the 2019 
ones from this study, further confirming that the MC might not influence BMI. 2020 
As the MC does not seem to affect body composition, parameters that are influenced by 2021 
it such as acceleration, power and V̇O2 (Esco et al., 2018; Janse de Jonge, 2003; 2022 





different sub-phases of the MC. In fact, as body mass and BMI did not significantly 2024 
change throughout the MC (Table 9), which helps to explain no differences in V̇O2, mean 2025 
power output and peak power output found between EF and ML. In contrast, peak 2026 
acceleration was found to be higher during ML than EF, but the body composition should 2027 
not be the reason behind the significant changes seen. 2028 
In this study no significant differences in BMI, fat mass or hips-to-waist circumference 2029 
were also found within the two sessions of familiarisation, EF or ML. In conclusion, it 2030 
appears that the hormonal fluctuations during the MC might not influence body 2031 
composition in any of the parameters analysed. 2032 
5.2 Physiological data 2033 
The findings of this study show that physiological parameters do not appear to be 2034 
influenced by the MC sub-phases. In fact, no significant differences between EF and ML 2035 
were found in any of the physiological parameters analysed. Further within-phase 2036 
comparison between two sessions during familiarisation, EF and ML also showed no 2037 
significant differences in any of the parameters. This could mean that the variability in 2038 
the hormone concentrations during the same sub-phase might not be enough to have a 2039 
real effect on these physiological variables. This was expected though, as the hormonal 2040 
differences during two days of the same sub-phase are reported to be lower than the 2041 
differences between EF and ML. As no effects were shown between EF and ML, where 2042 
the hormonal differences are at their greatest magnitude, it is not surprising that no 2043 
differences were found between two sessions of the same phase. 2044 
5.2.1 HR 2045 
The HR results from this study (EF: 159.08 ± 20.36 bpm, ML: 155.55 ± 20.43 bpm, p = 2046 
0.49) contrast with the hypothesis of a lower heart rate during EF when compared with 2047 





differences between the EF and ML sub-phases (Abdollahpor et al., 2013; Beidleman et 2049 
al., 1999; Bemben et al., 1995; De Souza et al., 1990; Dean et al., 2003; Lebrun et al., 2050 
1995; Oosthuyse et al., 2005). Even though a number of studies previously reported non-2051 
significant differences, significant differences were expected because it has been shown 2052 
that high concentrations of progesterone can increase HR, thus possibly causing a higher 2053 
HR during ML than EF. Janse de Jonge et al. (2012) have suggested that the HR would be 2054 
affected by changes in body temperature between the follicular and luteal phases. 2055 
However, the average increase in body temperature during the luteal phase (up to 0.6 2056 
°C) might be too low to significantly affect HR. The small effect size (d = 0.17), which 2057 
showed a trivial effect between EF and ML, further supports the conclusion that MC sub-2058 
phases do not significantly and meaningfully affect HR when performing a running RSA 2059 
(Figure 8). Basal body temperature was not monitored in this study, so it was not 2060 
possible to quantify the temperature difference between EF and ML. Nonetheless, it is 2061 
likely that the differences in temperature between the two sub-phases were consistent 2062 
with previous literature, and therefore did not significantly affect HR. 2063 
As HR has been shown to be correlated with RER and V̇O2 (Bot & Hollander, 2000; 2064 
Freedson & Miller, 2000; Habibi, Dehghan, Moghiseh, & Hasanzadeh, 2014; Ramos-2065 
Jiménez et al., 2008) it was expected to see that all of these parameters were found to 2066 
be non-significant. Furthermore, HR is one of the physiological determinants of RPE 2067 
(Hooper et al., 2011). Even though a significantly lower RPE (p < 0.001, d = 0.37) was 2068 
found during ML than EF, the role of HR in affecting RPE can be excluded due to its non-2069 
significant difference and the small effect size. 2070 
It is also important to consider that even though this study and the above-mentioned 2071 
studies found similar results, there were differences in participants’ fitness levels and 2072 
testing modalities. In fact, researchers used different exercise modalities (cycling, 2073 





to exhaustion. Moreover, participants’ fitness levels across the studies were wide-2075 
ranging from being non-active (Lamont, 1986; Oosthuyse et al., 2005), moderately active 2076 
(Bemben et al., 1995; Dean et al., 2003) or having a V̇O2max higher than 50 ml/kg/min 2077 
(Lebrun et al., 1995). Another fundamental aspect to consider is the method used to 2078 
determine the MC sub-phases. Whilst all of the studies that compared EF and ML used 2079 
blood sample to determine the sub-phases, the present study used a combined 2080 
approach of a urinary kit and a diary. However, similar results suggest that this combined 2081 
approach may be reliable enough to be used to determine MC sub-phases, particularly 2082 
in an applied sport setting. In conclusion, it appears that regardless the methodological 2083 
differences, HR does not appear to be significantly influenced by the MC during a running 2084 
RSA performance.  2085 
5.2.2 Lactate 2086 
The hypothesis that the lactate would be significantly lower during ML than EF was not 2087 
supported by our data, that showed no differences in pre-exercise lactate (EF: 1.43 ± 2088 
0.46 mmol·l-1, ML: 1.63 ± 0.51 mmol·l-1, p = 0.78) and post-exercise lactate (EF: 12.66 ± 2089 
3.11 mmol·l-1, ML: 12.01 ± 2.32 mmol·l-1, p = 0.58) (Figure 9). However, these results 2090 
agree with Lamont (1986), De Souza et al. (1990), Bemben et al. (1995), Abdollahpor et 2091 
al. (2013) and Dean et al. (2003) that reported non-significant differences between EF 2092 
and ML. As oestrogen and progesterone have been shown to affect energy metabolism 2093 
and substrate utilisation, and therefore lactate levels, this result was unexpected. A 2094 
possible explanation is that, even though oestrogen and progesterone can affect lactate 2095 
levels, the hormones difference between EF and ML were not big enough to show any 2096 
significant difference. The lack of differences between sub-phases suggests that no 2097 
metabolic changes (higher fat utilisation) occurred between EF and ML. This is further 2098 
confirmed by the fact that no significant differences were found in RER (EF: 1.11 ± 0.15, 2099 





utilisation did not change between sub-phases. To confirm the conclusion that the MC 2101 
sub-phases do not significantly and meaningfully affect pre- or post-exercise lactate, the 2102 
effect size showed a small effect in pre- and post-exercise lactate (d = 0.41 and d = 0.24, 2103 
respectively). Even though the present study and the above-mentioned studies found 2104 
non-significant lactate levels between EF and ML, participants with different fitness 2105 
levels were recruited to perform a range of exercises such as maximal exercises to 2106 
exhaustion and submaximal exercises during running and cycling. Thus, showing that the 2107 
results and conclusions reached do not seem to depend on the testing modalities and 2108 
participant’s fitness levels. Furthermore, different MC determination methods were 2109 
used. Whilst all the above-mentioned papers used blood samples to determine the sub-2110 
phases, in this study a different approach was used. This heterogeneity and the fact that 2111 
similar results were found suggest that the MC may not influence post-exercise lactate 2112 
regardless of the exercise modality, exercise choice, participant’s fitness level and MC 2113 
determination method.  2114 
5.2.3 V̇O2 2115 
In agreement with our hypothesis, no differences in V̇O2 between EF and ML were found 2116 
(EF: 35.65 ± 8.68 ml·kg-1·min-1, ML: 32.97 ± 8.97 ml·kg1·min-1, p = 0.10). Janse de Jonge 2117 
et al. (2003) offered an explanation by hypothesising that V̇O2max would be affected by 2118 
the MC only if the determinants of V̇O2max such as HR are also affected. Even though 2119 
the author was specifically referring to V̇O2max, a link between HR and V̇O2 is strong (Bot 2120 
& Hollander, 2000; Freedson & Miller, 2000; Habibi et al., 2014), which is demonstrated 2121 
by our findings as no significant differences in HR (Figure 8) are also reflected in no 2122 
significant changes in V̇O2 (Figure 10). This finding suggests that potential cardiovascular 2123 
changes related to MC hormonal fluctuations are not associated with changes in oxygen 2124 
uptake during repeated sprints (Gurd et al., 2007). Moreover, Figure 11 shows that RER 2125 





0.47). In fact, there is a strong association between RER and V̇O2 measures and it is very 2127 
likely that any changes in both of these parameters due to the effects of the MC sub-2128 
phases should follow similar pattern (Gurd et al., 2007; Ramos-Jiménez et al., 2008). 2129 
Moreover, the effect size between these two sub-phases was characterised as small (d 2130 
= 0.30), further providing evidence that the MC does not affect V̇O2 during RSA.  2131 
Similar results have been reported previously by Lamont (1986), De Souza et al. (1990), 2132 
Beidleman et al. (1999) and Janse de Jonge et al. (2012). These authors recruited 2133 
participants with different physical levels, including non-active participants that took 2134 
part in the study by Lamont (1986). Furthermore, all of those studies performed sub-2135 
maximal exercises at different intensities (60/70/80% V̇O2max) during running or cycling. 2136 
This is in contrasts to the active participants that were recruited in the current study to 2137 
perform a high-intensity repeated sprint exercise. This heterogeneity of participants and 2138 
exercises, considering that similar results and conclusion were reached, shows that the 2139 
effects of the MC on V̇O2 might not depend on the participants’ level or the exercise 2140 
tested. Further confirmation is found in a study by Middleton & Wenger (2006), which 2141 
analysed V̇O2 between the mid-follicular and late-luteal sub-phases during a RSA 2142 
exercise, and reported non-significant differences in V̇O2 during the sprints (mid-2143 
follicular: 24.3 ± 2.4 ml·kg1·min-1, late-luteal: 23.7 ± 1.5 ml·kg1·min-1). Even though 2144 
different sub-phases were compared, similar conclusions were reached, strengthening 2145 
the hypothesis that the MC might not affect V̇O2.  2146 
5.2.4 RER 2147 
Our hypothesis that a lower RER during ML compared with EF would be found was not 2148 
confirmed. The data from this study indicated no significant difference in RER between 2149 
EF and ML (EF: 1.11 ± 0.15, ML: 1.09 ± 0.16, p = 0.47), which suggests no differences in 2150 
fat utilisation between the two sub-phases occurred (Figure 11). Similar to lactate levels, 2151 





affect energy metabolism and substrate utilisation. Moreover, the same explanation 2153 
provided to explain the lack of significant differences in lactate levels can be used for 2154 
RER, as even though oestrogen and progesterone can affect RER, the hormones 2155 
difference between EF and ML might not big enough to show any significant difference. 2156 
The effect size was found to be trivial (d = 0.13), further confirming that the MC 2157 
hormonal fluctuations throughout sub-phases might not be enough to affect RER.  2158 
Non-significant differences in RER between EF and ML were also found by De Souza et 2159 
al. (1990), Dean et al. (2003), Janse de Jonge (2012), Lamont (1986), Lebrun et al. (1995), 2160 
and Oosthuyse et al. (2005). As there were methodological differences between the 2161 
current study and the others that reported similar conclusions, such as the test choice, 2162 
exercise modality and/or participants’ fitness level, it is possible that these differences 2163 
do not affect the results. A study by Middleton & Wenger (2006) is the only study that 2164 
analysed the effect of the MC on a RSA performance. The authors reported a significantly 2165 
lower (p = 0.04) RER during the late-luteal (1.17 ± 0.06) than the mid-follicular (1.19 ± 2166 
0.06) sub-phases, in contrast with the majority of the literature that reported non-2167 
significant differences. However, the difference (0.2) is quite small and is identical to the 2168 
absolute difference found in the present study (Figure 11). Albeit significant, the effect 2169 
size was not provided but the difference might be too small to be meaningful. In contrast 2170 
with the present study, Middleton & Wenger (2006) compared the mid-follicular and the 2171 
late-luteal sub-phases, instead of the early-follicular and mid-luteal one. Even though a 2172 
comparison of different sub-phases can lead to different results due to different 2173 
hormone concentrations, the biggest effect is expected when comparing EF and ML, as 2174 
they have the biggest difference in both oestrogen and progesterone among all the sub-2175 
phases. Because significant results were reported by Middleton & Wenger (2006) 2176 
between two sub-phases with a lower hormones difference, whilst all the studies that 2177 





contrasting results were due to another reason, unrelated to the hormonal fluctuations 2179 
during the MC.  2180 
As this study and all the papers mentioned included participants with different fitness 2181 
levels, to perform a variety of exercises, it does not appear that any of these differences 2182 
might have been the reason to explain the contrasting results from Middleton & Wenger 2183 
(2006). More studies about RSA are required to better understand the effects of the MC 2184 
on RER, during this specific performance. From the current literature and the present 2185 
study, it appears that the MC does not affect RER, regardless the methodological 2186 
differences among the studies. 2187 
5.2.5 V̇e 2188 
The hypothesis of a higher ventilation during ML when compared with EF was not 2189 
confirmed by our data, that showed non-significant differences (EF: 91.73 ± 19.82 l·min-2190 
1, ML: 89.10 ± 25.36 l·min-1, p = 0.42). However, in agreement with previous studies, V̇e 2191 
did not significantly differ between EF and ML (Beidleman et al., 1999; Bemben et al., 2192 
1995; De Souza et al., 1990; Lamont, 1986; Lebrun et al., 1995). The results were not 2193 
expected, as the hypothesis of a higher V̇e during ML than EF was formulated based on 2194 
previous studies showing that high concentrations of progesterone increase V̇e 2195 
(Beidleman et al., 1999; De Souza et al., 1990; Schoene, Robertson, Pierson, & Peterson, 2196 
1981; Williams & Krahenbuhl, 1997). A significantly higher V̇e was expected during ML 2197 
because of the highest concentration of progesterone throughout the MC is reached in 2198 
this sub-phase. Smekal et al. (2007) and Janse de Jonge et al. (2012) suggested that, 2199 
other than progesterone concentrations, factors like body temperature might affect V̇e, 2200 
but the differences in these factors between sub-phases might be too low to be 2201 
statistically significant. However, in the current study body temperature and 2202 
progesterone concentrations were not measured, and therefore the influence of these 2203 





suggested that other factors such as the central motor command might influence V̇e to 2205 
a greater extent thereby masking the effects of progesterone on V̇e. The trivial effect 2206 
size found between EF and ML (d = 0.12) enforces that conclusion that the MC does not 2207 
meaningfully affect V̇e. 2208 
In this study a non-significant higher V̇e was found in EF than ML, with a difference of 2209 
2.63 l·min-1. In contrast with our findings, Williams et al. (1997) reported a significantly 2210 
higher V̇e during ML than EF at 55% (5.2 l·min-1 difference) and 80% (4.0 l·min-1 2211 
difference) of V̇O2max. A RSA protocol was used in the current study, whereas Williams 2212 
et al. (1997) recruited participants to perform a submaximal running exercise. The 2213 
difference in testing protocol could explain the contrasting results. However, De Souza 2214 
et al. (1990), Lamont (1986) and Beidleman et al. (1999) all analysed similar protocols 2215 
(i.e. submaximal exercises at 70/80% V̇O2max) and reported non-significant results, 2216 
similar to the results of this study. It is also important to consider that whilst 5 studies 2217 
out of 6 reported non-significant differences in V̇e between EF and ML, the participants’ 2218 
fitness level, the exercise choice and modality were different. Thus, showing that these 2219 
methodological differences might not be relevant to determine whether the MC 2220 
influences V̇e. 2221 
From these findings, it might appear that progesterone does not stimulate ventilation 2222 
during the luteal phase or does not stimulate it enough to be significantly different. It is 2223 
recommended that future research studies look into the possible mechanisms as more 2224 
studies are required to understand how all the factors interact with the menstrual cycle 2225 
influence V̇e. However, from our data and the current literature it appears that MC does 2226 







5.3 Perceptual data (RPE) 2230 
The hypothesis of a lower RPE during EF than ML was not supported by our data that 2231 
showed the opposite effect, as a significantly lower RPE was found during ML when 2232 
compared with EF (EF: 13.42 ± 2.15, ML: 12.60 ± 2.26, p < 0.001). The findings from this 2233 
study contrasts with previous findings that did not report differences in RPE between EF 2234 
and ML (Beidleman et al., 1999; De Souza et al., 1990; Janse de Jonge et al., 2012).  2235 
To explain the significant differences in RPE in this study, the most likely explanation 2236 
would be the learning effect, where the participants became more familiar with the test 2237 
the more they performed it. The two familiarisation sessions may have not been enough 2238 
for the participants to feel comfortable with the protocol and the non-motorised 2239 
treadmill, and it is possible that the participants needed more than two sessions to be 2240 
ready to perform without seeing the influence of the learning effect (Figure 13). If more 2241 
familiarisation sessions were used, it is possible that the differences between EF and ML 2242 
would decrease and become non-significant. Even though there was no significant 2243 
difference in RPE between the familiarisation and EF, the RPE during the familiarisation 2244 
was higher (13.82 ± 1.91 vs 13.42 ± 2.15). This trend shows that the RPE values were 2245 
lower throughout the phases, showing the possibility that the athletes might have 2246 
become more familiar with the testing protocol, instead of meaning that the MC phases 2247 
actually affected the RPE score. This learning effect is further demonstrated by the fact 2248 
that the only participant that performed the test during ML first, showed a higher RPE 2249 
during this phase, and a lower RPE during EF (Figure 13). Moreover, significant 2250 
differences were also found between the two familiarisation sessions, with a higher 2251 
value during the first one (Figure 13). This difference can be again explained by the fact 2252 
that the participants became more familiar with the protocol and especially the non-2253 





However, it was reported to be rather unnatural running motion upon first use by every 2255 
participant. 2256 
In agreement with the hypothesis of a learning effect, a significantly lower RPE was also 2257 
found during ML than the familiarisation sessions (12.60 ± 2.26 vs 13.82 ± 1.91, p < 2258 
0.001). Furthermore, it is also important to consider that even though the differences 2259 
between EF and ML were significant, the effect size found was small (d = 0.37), showing 2260 
that the magnitude of the effect was little and strengthening the conclusion that the MC 2261 
might not affect RPE during RSA. 2262 
5.4 Performance data 2263 
Whilst mean power output, peak power output and distance were not affected by the 2264 
MC sub-phases, peak acceleration appeared to be influenced by it. The fact that power 2265 
output and distance were not affected by the MC might have important effects on sport 2266 
performance, as any sport that relies on short sprints might not be affected by the MC. 2267 
Furthermore, even though peak acceleration was found to be significantly different 2268 
between the two sub-phases (Figure 16), the distance did not significantly change. This 2269 
means that the changes in peak acceleration did not translate in a practical advantage 2270 
(distance). As peak acceleration captures a single instant during a sprint, it is possible 2271 
that this fraction of performance was not enough to significantly affect the distance 2272 
outcome (Figure 17). Therefore, RSA performance outcomes do not appear to be 2273 
influenced by the MC. 2274 
When comparing two sessions of the same sub-phase, no differences in peak/mean 2275 
power, peak acceleration or distance were found during the familiarisation, EF or ML. 2276 
This strengthens the previous point that the variability within hormonal concentrations 2277 





expected, as the hormonal differences during two days of the same sub-phase are 2279 
reported to be lower than the differences between EF and ML. 2280 
5.4.1 Power output 2281 
The findings from this study confirms our hypothesis, as no differences were found 2282 
between EF and ML in mean (EF: 1406.33 ± 208.97 W, ML: 1405.71 ± 212.86 W, p = 2283 
0.998) and peak power output (EF: 2498.32 ± 383.56 W, ML: 2432.75 ± 417.10 W, p = 2284 
0.14). It has been hypothesised by Pestana et al. (2017) that power output might be 2285 
affected by changes in body composition. However, the lack of significant differences 2286 
between EF and ML in fat mass and BMI (Table 9) can explain the power output results 2287 
(Figures 14 and 15), as no changes in body mass and muscle mass were found. 2288 
Furthermore, the effect size for mean and peak power output was found to be trivial (d 2289 
= 0.00 and d = 0.16 respectively) and is similar to the small effect sizes found in BMI and 2290 
fat mass, showing that the effect of the MC on power output might be meaningless. 2291 
The findings agree with those by Kose et al. (2018), who reported non-significant 2292 
differences between the same sub-phases during a Wingate anaerobic test, in mean and 2293 
peak power output. Even though the Wingate anaerobic test and running RSA do not 2294 
appear to be correlated (Aziz & Chuan, 2004), both tests measure anaerobic power 2295 
output, and therefore the results can be used for comparison purposes. However, it has 2296 
to be taken into consideration that the two protocols were different, and therefore this 2297 
comparison has to be taken with caution. This difference can be seen from the data, as 2298 
the MPO found in this study (EF: 1406.33 ± 208.97 W, ML: 1405.71± 212.86 W) highly 2299 
differs from Kose et al.’s (2018) results (EF: 379.43 ± 69.23 W, ML: 377.75 ± 66.86 W). 2300 
However, the mean difference in MPO between the two sub-phases in the present study 2301 
was 0.62 W, which is similar to a 1.68 W difference reported by Kose et al. (2018). A big 2302 
difference was also found in PPO between the study (EF: 2498.32 ± 383.56 W, ML: 2303 





W). The differences in PPO between the two studies were higher, with a 65.57 W 2305 
difference found in this study, and a 0.94 W reported by Kose et al. (2018). 2306 
The study by Middleton & Wenger (2006) analysed a RSA performance a reported non-2307 
significant differences in peak power between the mid-follicular (6.8 ± 0.6 W·kg-1) and 2308 
late-luteal (6.9 ± 0.6·kg-1) sub-phases, reaching the same conclusions as the present 2309 
study. Even though different sub-phases were analysed, the results reported by 2310 
Middleton & Wenger (2006) strengthen the conclusion that the MC might not influence 2311 
power output.  2312 
No significant differences were found in the fatigue index for MPO and PPO between EF 2313 
and ML, and similar results reported by Tsampoukos et al. (2010) between the follicular 2314 
and the luteal phase. However, a significant difference in the fatigue index for PPO was 2315 
found between the two sessions of the familiarisation, whilst no differences were found 2316 
between the sessions of EF or ML. This shows the importance of the familiarisation 2317 
sessions prior to the data collection, to reduce variability and avoid any learning effect. 2318 
Future studies should take into consideration these results and include at least two 2319 
familiarisation sessions to avoid possible unreliable results. 2320 
5.4.2 Peak acceleration 2321 
In contrast with our hypothesis, a significant higher peak acceleration was found during 2322 
ML when compared with EF (EF: 4.65 ± 0.84 m·s-2, ML: 5.05 ± 1.14 m·s-2, p = 0.02). This 2323 
result was not expected, because even though acceleration have never been studied 2324 
before and no results are available for a comparison, there is an overall consensus that 2325 
the MC does not affect different types of performances such as incremental test to 2326 
exhaustion, submaximal tests or the Wingate’s tests. Without having previous data on 2327 





performance to peak acceleration, and therefore no significant differences were 2329 
expected.  2330 
Albeit significant, the effect size calculated showed a small effect (d = 0.40), indicating 2331 
that the difference in peak acceleration might not be meaningful. Moreover, looking at 2332 
individual data it can be seen that only 3 participants had a higher peak acceleration 2333 
during ML, whilst 2 of them showed the opposite result. This split in the individual results 2334 
highlights the need to conduct more research and gather more data. Peak acceleration 2335 
was also found to significantly differ between the familiarisation (4.66 ± 0.77 m·s-2) and 2336 
ML (5.05 ± 1.14 m·s-2) (p = 0.04, d = 0.40).  2337 
A possible explanation to justify the higher peak acceleration during ML would be the 2338 
learning effect, where the participants had a better performance during ML because 2339 
they had the time to get more comfortable with the non-motorised treadmill and the 2340 
protocol, allowing them to perform better. However, if the learning effect was the cause, 2341 
we should have seen a difference between the familiarisation and EF too and a more 2342 
constant improvement. Instead, a non-significant and very small difference was found 2343 
between the familiarisation and EF (0.01 m·s-2), showing that the learning effect might 2344 
not be the explanation for the significant difference between the familiarisation and ML, 2345 
and between EF and ML. This is also confirmed by the peak acceleration values between 2346 
all the 6 sessions that did not have a stable increase in value. If the learning effect were 2347 
the cause for a higher performance, the peak acceleration would probably have a more 2348 
stable increase in values, and not a decrease from the second session of the 2349 
familiarisation to the first one during EF (4.79 ± 0.87 m·s-2 vs 4.66 ± 0.87 m·s-2). 2350 
A significant difference was also found in the fatigue index for acceleration between the 2351 
familiarisation and ML. The highest value in the score decrement was found during the 2352 
familiarisation, and decreased during both EF and ML. The decrease between the 2353 





familiarisation sessions were performed. A lower score decrement means that the 2355 
performance was more stable between each of the consecutive sprints, which is a 2356 
consequence of being more comfortable with an exercise such as repeated sprints. This 2357 
result shows the importance and the usefulness of the familiarisation sessions. 2358 
5.4.3 Distance 2359 
In agreement with our hypothesis, no differences were found in distance between EF 2360 
and ML (EF: 20.47 ± 2.44 m, ML: 20.31 ± 2.47 m, p = 0.59). This lack of significance can 2361 
be explained by the fact that power output was also non-significant. In fact, a strong 2362 
relationship between power output and sprint performance exists, especially for shorter 2363 
sprints (Haugen, Seiler, Sandbakk, & Tønnessen, 2019). The conclusion that the MC 2364 
might not affect the distance finds further confirmation in the effect size (d = 0.07), 2365 
which showed trivial differences between the two sub-phases. 2366 
These findings are in agreement with Julian et al. (2017), that also reported no significant 2367 
differences between EF and ML (3289 ± 801 m vs 2822 ± 896 m respectively) during a 2368 
Yo-Yo intermittent endurance test (Yo-Yo IET). However, Julian et al. (2017) tested the 2369 
participants during a long-distance aerobic performance, whilst there are no studies that 2370 
tested a short performance and reported the distance as a parameter. The findings from 2371 
Julian et al. (2017) can be explained by the fact that distance during a Yo-Yo IET has been 2372 
linked with V̇O2max, which is not influenced by the menstrual cycle phases. As previously 2373 
stated, V̇O2 is also an important factor for RSA performance, and we did not find any 2374 
differences in V̇O2 during the two sub-phases analysed (Figure 10), this could also justify 2375 
the lack of significant differences in distance between EF and ML.  2376 
5.5 Limitations 2377 
There are a few major limitations in this study that could be addressed in future 2378 





draw definitive conclusions, and it can influence the research findings as a small sample 2380 
size can undermine the internal and external validity of a study (Faber & Fonseca, 2014). 2381 
This limitation in participant numbers is also evident in most previous studies looking at 2382 
the effects of the MC on sport performance, and it should be addressed in the future.  2383 
As previously explained, the low sample size was due to difficulties in recruiting and due 2384 
to the limited time available to complete the project. Therefore, when planning similar 2385 
studies researchers should be aware of the time-commitment as well as other 2386 
challenges, including recruitment, inclusion/exclusion criteria and dropout rates. Most 2387 
of the criteria are necessary to study the effects of the menstrual cycle on performance 2388 
and cannot be removed. I would suggest that a collaboration between multiple 2389 
researchers and universities might be the best bet to achieve a large sample size and 2390 
more meaningful results. 2391 
However, to strengthen this study each test was repeated twice during each MC sub-2392 
phase and during the familiarisation. Even though this does not make up for the low 2393 
sample size, it helps in reducing the variability, and therefore strengthening the results. 2394 
Alongside a general female underrepresentation in sport and exercise research as stated 2395 
in the Introduction, another possible reason for small sample sizes in similar studies is 2396 
that 49.5% of athletes are reported to use hormonal contraceptives, and 69.8% used one 2397 
at some point (Martin, Sale, Cooper, & Elliott-Sale, 2018), showing that the available 2398 
athletic population not using any hormonal contraceptives is greatly reduced. If we 2399 
combine this data with the fact that only 61% of women are active (Sport England, 2019), 2400 
this presents some clear challenges in recruiting female participants, because it shows 2401 
that the available population that meets the inclusion criteria of being active and not 2402 





Furthermore, other inclusion criteria had to be met to participate in this project, further 2404 
reducing the available population. All the participants had to be training at least three 2405 
times per week for a full year (any form of training) and had to be healthy, non-smokers 2406 
and not under any kind medication or treatment that could influence hormones or 2407 
performance. Furthermore, the menstrual cycle had to be regular and with an average 2408 
length between 24 and 35 days. Another reason is the drop out from the experiment, as 2409 
2 participants were excluded because they started to use hormonal and contraceptive 2410 
medications, and one participant could not finish all the sessions due to medical issues. 2411 
All these factors are important to consider, when trying to understand the difficulties in 2412 
recruiting, as they lead to low sample sizes, and are the reason why researchers tend not 2413 
to recruit females in their studies, as the high number of criteria and limitations would 2414 
create practical problems with the recruitment. Furthermore, this challenge is amplified 2415 
when the objective of the study is directly related to the MC, where more extensive 2416 
criteria are applied. 2417 
 2418 




























The second major limitation is the determination of the MC sub-phases, as the combined 2420 
approach chosen did not guarantee the exclusion of LPD participants and did not provide 2421 
hormonal values to be used to confirm the MC sub-phases. This approach was used 2422 
because of its practicality and low cost, that allow it to be used by practitioners, whilst 2423 
also being considered accurate. This aspect is fundamental, because the possibility to 2424 
measure hormonal concentrations would allow a better comprehension of the results. 2425 
In fact, differences in results might be due to different ranges of hormones among 2426 
participants in the studies (Beidleman et al., 1999), or high intra-individual variability of 2427 
hormone concentration (Beidleman et al., 1999). 2428 
Another limitation of this study is that the sessions were not done at the same time of 2429 
the day, exposing the results to circadian variations in RPE and hormonal fluctuations 2430 
and potentially affecting the results. The participants were asked to come to the lab at 2431 
the same time on each session, but it has not been always possible due to work, study 2432 
or personal reasons. Future studies should take this factor into consideration and test 2433 
the participants at the same time of the day. 2434 
Prior to the intervention, participants were asked if they needed to void their bladder 2435 
and encouraged to do so. However, whether they voided their bladder or not was not 2436 
confirmed and should be taken in consideration for future studies in order to avoid its 2437 
effect on body mass measurements. 2438 
Finally, the fitness level criteria used in the current study were based on training time 2439 
and frequency, which does not really reflect the training status of a person. This choice 2440 
was made because of recruitment problems, as using more strict criteria could have 2441 
reduced the sample size even further. Therefore, future studies using female athletes 2442 






5.6 Recommendations 2445 
Due to the limitations of this study and of the previous studies that analysed the effects 2446 
of the MC phases on performance, the main recommendation would be to start by 2447 
addressing the small sample size and the lack of a standardised way to determine the 2448 
MC sub-phases. Furthermore, future studies should consider all the sub-phases of the 2449 
MC and their effect on RSA performance, as this study only considered EF and ML 2450 
whereas comparisons between other sub-phases may lead to different findings.  2451 
Additionally, it would be interesting to also look at participants using hormonal 2452 
contraceptives. Sims & Heather, 2018, explained how oral contraceptives could be used 2453 
in future experimental designs by helping to examine the effects of downregulated 2454 
hormones concentrations on performance, and to investigate the differences between 2455 
exogenous and endogenous hormones on performance. 2456 
Moreover, participants with different fitness levels should be included in future studies. 2457 
Both non-active participants and professional athletes should be tested, and their results 2458 
analysed. To do that, it is imperative to use objective fitness criteria in order to 2459 
determine participants’ fitness levels.  2460 
Another possible suggestion for future research would be to include other hormones, 2461 
instead of focusing on oestrogens and progesterone only. For example, androgens could 2462 
be included due to their influence on performance (Bermon, 2017). Not looking at other 2463 
hormones and their interaction with the menstrual cycle might be considered a 2464 
limitation. 2465 
The findings of the current study show the importance of familiarisation in order to 2466 
minimise the learning effect in any future studies. In the current study, RPE results were 2467 





visible. We recommend a minimum of two familiarisation sessions before starting any 2469 
testing as failure to do so may lead to the inaccurate interpretation of the findings.  2470 
5.7 Practical applications 2471 
From a practical point of view, these results indicate that coaches and athletes might not 2472 
have to tailor RSA training and testing based on the MC sub-phases. However, due to the 2473 
low statistical power of this study, more data are required to address the research 2474 
questions of this project with more certainty. This could mean that, even though during 2475 
the MC a participant might report pain or discomfort (Giacomoni et al., 2000; Hooper et 2476 
al., 2011; Kishali, Imamoglu, Katkat, Atan, & Akyol, 2006), this might not affect the 2477 
results/performance. The current findings also highlight inter-individual variation across 2478 
all reported measures, which shows that individual responses should be closely 2479 
monitored.  2480 
However, this interpretation of the results is strictly related to the outcome of the 2481 
performance (i.e. distance in each sprint) and does not properly consider the 2482 
psychological aspects behind the performance and trainings and therefore might be 2483 
limited. In fact, athlete’s feelings and sensations should not be discarded just because 2484 
they do not directly result in a lower performance. A recent study by Findlay et al. (2020) 2485 
reported that 93% of the participants reported negative MC related symptoms such as 2486 
worry, distraction and lack of motivation, and 67% of the participants considered that 2487 
those symptoms impaired their performance. Furthermore, two participants reported 2488 
that they were not able to complete a training session due to pain or dysmenorrhea 2489 
(Findlay, Macrae, Whyte, Easton, & Forrest, 2020). This might negatively impact athletes’ 2490 
performance level, especially if this occurs at multiple times during the competitive 2491 





Even though from the current study and the existing literature it appears there are no 2493 
differences in physiological parameters, Findlay et al. (2020) outlined that several 2494 
athletes are still reporting negative perceptions. Therefore, practitioners should take 2495 
these perceptions in consideration when working with female athletes. The relationship 2496 
between an athlete and the coaching staff is fundamental and addressing what an 2497 
athlete reports might help build a relationship of trust as well as optimise their training 2498 
programme. In contrast, ignoring how they feel might lead to sub-optimal performance. 2499 
The coaching staff should follow an evidence-based approach by monitoring each 2500 
athlete’s MC, openly discussing the possible effects of MC on performance, and where 2501 
required adapting their training programmes based on the athletes’ subjective feelings. 2502 
A personalised approach based on each athlete’s responses to the menstrual cycle and 2503 
















6. Conclusions 2516 
The findings of the current study demonstrate that RSA performance is not influenced 2517 
by the menstrual cycle sub-phases. Even though the sample size limits the statistical 2518 
power of this study, as there were no previous studies about the effects of the MC on 2519 
repeated sprint ability these results provide a first insight of the effects of early-follicular 2520 
and mid-luteal sub-phases on RSA. The results from this project could benefit other 2521 
research in this field, by informing about the methodology used and the limitations 2522 
found, and by providing data and results to be used. Furthermore, it can provide useful 2523 
information for practitioners about how to organise their training sessions around the 2524 
menstrual cycle. However, further studies are required to be able to fully understand if 2525 
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